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 ABSTRACT 
Dendritic cells (DCs) modified by some immunomodulatory genes can stimulate a strong 
antitumor immunity and improve the treatment of tumor cells on the condition that the 
sources of tumor-associated antigens (TAAs) are available. IL-6, a pleotropic cytokine, has 
been found to inhibit CD4+25+ regulatory T (Treg)-cell-mediated immune suppression and 
decrease activation-induced cell death (AICD) without interfering the process of T-cell 
activation. To enhance DC-based cancer vaccine, we engineered DCs to express transgene 
IL-6. 
We constructed a fiber-modified recombinant adenovirus vector AdVIL-6 expressing IL-6, 
infected DCs with AdVIL-6, and then investigated the efficacy of antitumor immunity induced 
by vaccination with DCs engineered to express IL-6 transgene. We demonstrated that DCs 
infected with the recombinant adenovirus AdVIL-6 induced DC maturation by up-regulation 
of the expression of MHC class Ⅱ  (Iab), CD40, CD54 and CD80 expression. We also 
demonstrated that vaccination of OVA-pulsed AdVIL-6-infected DCs (DCOVA/AdVIL-6) was 
able to stimulate a stronger OVA-specific effector CD8+ cytotoxic T lymphocyte (CTL) 
response than vaccination with the control virus AdVpLpA-infected DCs (DCOVA/AdVpLpA). 
More importantly, vaccination of mice with DCOVA/AdVpLpA could protect 100% mice from 
intravenous (i.v.) challenge of a low dose (0.5×105 cells per mouse, 8/8 mice protected) of 
OVA-expressing BL6-10OVA tumor cells, but only 63% mice from i.v. challenge of a high 
dose (1×105 cells per mouse, 5/8 mice protected) of BL6-10OVA tumor cells. However, 
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 vaccination of DCOVA/AdVIL-6 induced an augmented antitumor immunity in vivo by complete 
protection of mice (8/8) from challenge of both low and high doses of BL6-10OVA tumor cells. 
To study the immune mechanism underlying the result of IL-6 engineered-DC vaccine, we 
generated the DCOVA/AdVIL-6-activated OTI CD8+ T cells and DCOVA/AdVpLpA-activated OTI 
CD8+ T cells. We demonstrated that DCOVA/AdVIL-6-activated CD8+ T cells displayed a higher 
level of CD62L, FasL and perforin than DCOVA/AdVpLpA-activated CD8+ T cells. DCOVA/AdVIL-
6-activated CD8+ T cells had a prolonged T cell survival after they were transferred into 
C57BL/6 mice. Furthermore, the results of the animal study showed that 100% of mice 
bearing OVA-expressing EG7 tumors (8mm in diameter, 8 mice per group) were tumor-free 
after they were i.v. treated with DCOVA/AdVIL-6-activated CD8+ T cells (2×106 cells per mouse). 
However, the control DCOVA/AdVpLpA-activated CD8+ T cells failed in eradication of EG7 
tumors in all 8/8 mice.  
Taken together, Adenovirus-mediated IL-6 transgene engineered DC vaccine stimulates 
efficient CD8+ T cell responses and antitumor immunity via enhanced T cell cytotoxicity and 
prolonged T cell survival. DCs engineered to express IL-6 by adenovirus-mediated IL-6 gene 
transfer may offer a new strategy in production of DC cancer vaccines. 
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Chapter 1 
REVIEW OF THE LITERATURE 
1.1 Introduction 
Cancer is a severe disease and has a very high risk of death. The World Health 
Organization (WHO) reported that cancer was responsible for about 13% of all deaths in 
2007. Based on data from the American Cancer Society (ACS), 7.6 million people died 
from cancer worldwide in 2007. We have spent a lot of money and time to find out 
effective treatments to conquer this disease. However, still there are many problems with 
cancer therapy that need to be addressed. Today, the most frequently used treatments for 
malignant tumors consist of surgery, chemotherapy and radiation therapy. Theoretically, 
surgery is able to cure non-hematological cancer by complete removal of tumor cells. 
However, once tumor cells have metastasized to distant sites, surgical therapy is usually 
not viable. Both chemotherapy and radiation lack specificity for tumor cells, and cause 
damage to normal tissue, resulting in severe side-effects. The goal of cancer treatment is 
to remove cancer cells completely without damaging normal cells. Thus, a specific 
treatment approach is required for curing cancer. In past decades, research has focused on 
immune cell-based strategies for the treatment of human cancer. Cancer immunotherapy 
is able to eliminate the tumors via immune system responses. This therapy may reach the 
goal of cancer treatment without damage to normal tissues.  
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1.2 Immune Responses 
The immune system in animals and humans is a collection of mechanisms to prevent the 
infection of pathogens, such as bacteria, viruses and tumor cells. The innate immune 
system and the adaptive immune system are the two components of the immune system. 
The innate immune system, found in nearly all forms of life, responds in a non-specific 
manner. In the innate immune system, infectious agents are recognized and killed by 
phagocytic cells. Some phagocytic cells, such as natural killer (NK) cells, dendritic cells 
(DCs) and macrophages, are not only involved in the innate immune system, but also 
participate in the adaptive response. These cells form a bridge between these two kinds of 
immune systems. Unlike innate immune responses, the adaptive immune system, only 
found in jawed vertebrates, can lead to antigen-specific responses and immunological 
memory. In the adaptive immune responses, powerful antigen presenting cells (APCs), 
such as DCs, macrophages and B cells, are required to recognize the specific “non-self” 
antigens and then generate immune responses. Two kinds of immune responses are 
included in the adaptive immune system, cellular immunity and humoral immunity. 
Humoral immunity refers to the production of secreted antibodies, which are produced by 
activated B cells. The process of B cell activation involves helper T cell interaction with 
B cells as well as cytokine productions. These antibodies can eliminate their specific 
antigen via pathogen and toxin neutralization, classical complement activation, 
opsonization and phagocytosis.  In cellular immunity, T lymphocytes are activated via 
APCs. These activated T lymphocytes kill phagocytosed microbes and lyse infected cells. 
After the initial immune response, B and T memory cells appear in the blood and will 
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bring a stronger and more effective immune response upon repeat encounters with the 
same pathogen. 
1.3 Tumor-associated Antigens (TAAs) 
Tumor-associated antigens (TAAs), which can be targeted using T cell-immunotherapy, 
play an important role in the adaptive immune system. These antigens, produced in some 
tumor cells and also some normal cells, trigger an antitumor immune response in the host. 
Serological expression cloning is a technology for identification of TAAs from different 
tumors. Their ability to identify tumor cells makes TAAs potential candidates in cancer 
therapy. TAA contain several categories (1): 
Shared tumor-specific antigens are a group of tumor antigens and include melanoma 
antigen (MAGE)-type gene families (MAGE-1 to 10, B melanoma antigen (BAGE), G 
melanoma antigen (GAGE) and synovial sarcoma on X chromosome (SSX)-1 to 9) (2). 
They are usually silent in normal tissues except in testis, but are expressed in a broad 
range of tumors, particularly melanomas and carcinomas of the lung, head, neck, bladder, 
and esophagus. However, their expression is absent or infrequent in renal carcinoma and 
leukemia. 
Some melanoma-reactive T cells can recognize melanocyte differentiation gene 
products, including melan-A/melanoma antigen recognized by T cell (MART-1), 
glycoprotein-100 (gp100), tyrosinase, tyrosinase-related protein (TRP)-1 and TRP-2. 
These antigens can be targeted if they are significantly over-expressed in malignant cells 
or if the normal cells involved are not functionally important. These antigens are also 
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present in normal melanocytes. T cell recognizes melanocyte differentiation antigens in a 
conventional class I and class II restricted manner. These antigens are the frequently used 
target of melanoma-reactive T cells.  However, the activated T cell will cause 
autoimmunity in the form of vitiligo, or less frequently uveitis (3, 4). 
Viruses are recognized as a major etiologic factor in human cancer. The percentage of 
virus-induced cancer is 15% to 20% (5, 6). Viruses involved in human cancers are 
Epstein-Barr virus (EBV), human T-cell lymphotropic virus type I (HYLV-1), human 
herpes virus type 8 (HHV-8), hepatitis B and C viruses (HBV and HCV, respectively), 
and human papillomavirus (HPV) type 16 and 18 (and other less prevalent oncogenic-
HPV types). Some antigens from these oncogenic viruses can be targeted in the immune 
system. 
Some oncoprotein /receptors and mutations, which occur in oncogenes and tumor 
suppressor genes, meet the two important criteria of a good tumor antigen :(i) over-
expression in the tumor and low expression in normal cells or unique expression in the 
tumor cell that allows the immune system to distinguish cancer cells from normal cells 
and (ii) mandatory function of the protein for malignant transformation, preventing the 
tumor from escaping the immune response by suppressing expression of the antigen 
without losing its malignant phenotype (1). For these reasons, antigens from this group, 
such as human epidermal growth factor receptor (HER)-2/neu, mutant ras or mutant p53, 
are probably the most ideal and have been widely studied as potential tumor antigens 
against which immunotherapeutic vaccines are targeted. Mutant ras are present in a broad 
spectrum of cancers, including adenocarcinoma of the pancreas, colorectal 
   5
adenocarcinoma, lung adenocarcinoma, thyroid tumor and myeloid leukemia, but are not 
present in normal cells (7). HER-2/neu is over-expressed in approximately 25-30% of 
invasive breast cancers (8, 9) and in ovarian (10) and lung cancers (11). 
Finally, carbohydrate antigens, which are expressed as glycolipids or glycoproteins at 
the tumor cell surface, have proven to be potent targets for antibody recognition. These 
antigens also attack cancer cells due to their unexpected immunogenicity and their 
abundance at the normal cell surface. GM2, GD2 and GD3 are three of the most well 
known melanoma glycoproteins. These three glycoproteins are also expressed in sarcoma 
neuroblastoma, colon, ovary and stomach cancer.  
1.4 Dendrite cells (DCs) 
DCs, which are powerful APCs, uptake antigens efficiently via macropinocytosis, 
receptor-mediated endocytosis and engulfment of apoptotic bodies. There are four stages 
of development in the life cycle of DCs, including DC progenitors, precursor DCs, 
immature DCs and mature DCs. The DC progenitors in the bone marrow can develop to 
be circulating precursor DCs. After encountering an antigen (Ag), these DCs induce 
secretion of cytokines, such as interferon- α (IFN-α), to activate the eosinophils, 
macrophages and NK cells for the innate immune response and also enter tissues to 
become immature DCs for induction of the adaptive immune response. Tissue-residing 
immature DCs can capture Ag due to their high endocytic and phagocytic capacities. In 
the periphery, immature DCs capture antigens and migrate to secondary lymphoid organs. 
In these locations, immature DCs develop to mature DCs, expressing high levels of major 
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histocompatibility complex (MHC) class II molecules, costimulatory molecules, such as 
CD80, CD86, CD40, and adhesion molecules, such as intracellular adhesion molecule 
(ICAM)-1, as well as some cytokines. Mature DCs select rare circulating antigen-specific 
lymphocytes and activate these immune effector cells, including the CD8+ cytotoxic T 
cells, CD4+ T helper (Th) cells and B cells. Mature DCs have high stimulatory activity 
for T lymphocyte cells. In the mixed lymphocyte reaction, one DC could activate three 
thousand naive T cells. After activation, T lymphocytes migrate to the injured tissue 
where the cytotoxic T cells will lyse the infected cells and the Th cells will activate 
macrophages, NK cells, and eosinophils (12) through secreting some cytokines. The 
activation of B cells requires the interaction of the activated Th cells and mature DCs. 
After activation, B cells mature into plasma cells and migrate into different areas to 
produce antibodies. Finally, mature DCs die via apoptosis after interaction with 
lymphocytes (13). 
Based on the above description, DCs also play an important role in both the innate and 
adaptive immunity of the antitumor immune response. In innate immunity, after 
recognizing tumor pathogen associated molecular patterns (PAMP), the circulating 
precursor DCs release IFN-α to activate macrophages, NK T cells, and NK cells. These 
cells kill tumors, leading to the release of tumor cell bodies. By capturing the TAAs 
released by those tumor cell bodies, the tissue-residing immature DCs become mature 
and display tumor antigens for selection of tumor specific T lymphocytes, including 
CD4+ and CD8+ T cells. The activated TAA-specific T cells home to the tumor sites and 
eliminate these tumor cells, inducing a cellular immune response(13). Based on these 
   7
powerful important roles of DCs, DC-based vaccines have been proposed as a treatment 
modality for cancer. 
1.5 Dendrite cell (DC) –based Vaccines 
1.5.1 Tumor Antigen-pulsed DC Vaccines 
It has been suggested that the tumor-antigen-pulsed DCs can induce the development of 
MHC- class I (MHC I) - and class II (MHC II)-specific T cell responses in vitro and in 
vivo.  Tumor antigen-pulsed DC vaccine development includes two kinds of approaches, 
pulsing DCs with specific tumor peptide and loading DCs with total tumor lysate 
antigens.  
It is reported that when delivered to animals, vaccines consisting of DCs pulsed in vitro 
with peptide antigen can induce antigen-specific, cytotoxic T lymphocyte (CTL) - 
mediated protection against lethal tumor challenges. Moreover, these DCs pulsed in vitro 
with peptide antigen elicit a therapeutic antitumor immunity in vivo (14). The tumor 
specific antigen-pulsed DCs have been used in animal studies and clinical trials, and have 
been shown to have more or less beneficial effects. The MHC-restricted synthetic tumor 
specific peptides that were used in animal models include Mutator (Mut) I (15), 
Ovalbumin (OVA) (15), gp70/p15E (16) HER2/neu (17) and fusion protein breakpoint 
cluster regional/antigen-binding lymphocyte (BCR-ABL) (18). In clinical trials, DCs 
pulsed with melanoma related antigens have been used to treat melanoma tumors and this 
vaccination has induced antigen-specific immunity (19-21) Furthermore, the HER/neu 
(22) and MUC-1 (23) were used to pulse DCs to cure tumors that over-express these two 
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antigens. In patients with these tumors, the effector immune responses can be induced by 
these vaccinations.  
However, vaccination with DCs pulsed by specific tumor peptides only stimulate a CTL 
response in the immune system and have no effect on MHC class-Ⅱ-restricted Th cells 
which initiate and sustain immune responses. Additionally, it is difficult to identify and 
generate a specific antigen peptide for some tumors. Based on these two points, whole 
tumor lysate antigens were used to pulse DCs in vitro. The use of whole tumor lysate 
antigens as a source of antigen to pulse DCs induces not only CTL responses, but also 
helper T cell responses, which is important to achieve a more complete anti-tumor 
response.  Therefore, DCs loaded with whole tumor lysate antigens are very effective for 
tumor vaccine strategies. It was reported that in two separate strains of mice with 
histological distinct tumors, DCs pulsed with whole tumor lysate antigens mediate potent 
antitumor immune responses in vitro and in vivo (24). In clinical trials, vaccinations using 
DCs loaded with whole tumor lysate antigens have been shown to be valuable in the 
treatment of malignant melanoma (19), brain tumor (25, 26) uterine serous papillary 
cancer (27), renal cell carcinoma (28, 29)and pediatric solid tumor (30). 
1.5.2 Tumor mRNA-pulsed or Transfected DC Vaccines 
DCs pulsed or transfected with tumor mRNA translate the respective tumor proteins and 
induce CTL responses. The advantages of these vaccines are that: (i) these vaccines can 
work irrespective of the patient’s human leukocyte antigen (HLA) repertoire because 
these translated tumor proteins have wide HLA specificities and (ii)It is easy to isolate 
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the tumor mRNA from animal or human tumor cells and amplify these mRNAs 
conveniently without loss of function (31, 32). There are two approaches to deliver the 
tumor mRNA to DCs, including mRNA lipofection and mRNA electroporation into 
human hematopoietic cells. Although the latter method possesses a higher efficiency, 
mRNA/liposome complexes are more widely used (33, 34). Tumor mRNA-pulsed or 
transfected DCs can encode not only the tumor antigen but also the costimulatory 
molecular. During this process, the DCs become mature and mediate the tumor antigen 
peptide to MHC I and MHC II molecules. Finally, T cell responses are induced by this 
DC vaccine.  
It was reported that murine DCs transfected with RNA amplified from the melanoma 
B16/F10.9 cell line can induce CTL responses in mice and stimulate protective immunity 
in tumor-bearing mice (31).  Shigeo Koido et al reported that vaccination of wild-type 
mice with MUC1 RNA-transfected DCs induced anti-MUC1 immune responses against 
MUC1-positive, but not MUC1-negative, MC38/MUC1 tumor cells. Mice immunized 
with the transfected DCs were protected against challenge with MC38/MUC1 tumor cells. 
Furthermore, the established MC38/MUC1 tumors in mice were eliminated after 
receiving the vaccination (35). During clinical trials, there are some limitations with 
tumor mRNA-pulsed or transfected DC vaccines, which have been used in the treatment 
of colorectal cancer (36), bladder cancer (37) and renal tumors (38). However, Axel 
Heiser et al found that total tumor RNA-transfected DCs may represent a widely 
applicable vaccine strategy to induce potentially therapeutic polyclonal T-cell responses 
in cancer patients (38). 
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1.5.3 Necrotic or Apoptotic Tumor Cell-loaded DC Vaccines 
DCs can recognize and uptake apoptotic and necrotic tumor cells via specific receptors, 
such as αvβ5, CD36 or the phosphatidylserine receptor for apoptotic tumor cells (39), and 
CD91, the receptor for heat shock protein (HSP) expressed on necrotic tumor cells (40, 
41). After uptake of the apoptotic and necrotic tumor cells, DCs present or cross-present 
both MHC I and MHC II epitopes of a defined tumor antigen or multiple tumor antigens 
(42-44). This vaccine does not rely on the HLA haplotype and can be utilized for all 
patients. The stage of apoptosis of the tumor cell significantly affects DC maturation and 
induction of antitumor immunity. It has been shown that only late-phase, not early-phase, 
apoptotic tumor cells can stimulate DC maturation and lead to the induction of antitumor 
immunity (45). Moreover, because DCs recognize and uptake necrotic tumor cells via 
CD91 and HSP, the level of HSP exposed on necrotic tumor cells plays a key role in the 
maturation of  DCs and stimulation of antitumor immunity (46, 47).  Our lab reported 
that DC-mediated phagocytosis of necrotic or apoptotic tumor cells induces DC 
maturation, resulting in the up-regulation of pro-inflammatory cytokines (interleukin 
(IL)-1β, IL-6, tumor necrosis factor-α (TNF- α), IFN-γ and granulocyte-macrophage 
colony-stimulating factor (GM-CSF)) and chemokines (macrophage inflammatory 
protein (MIP)-1α, MIP-1β and MIP-2), and the expression of co-immunostimulatory 
molecules (CD40 and CD86). Moreover, our data also showed that vaccination with DCs 
that had phagocytosed apoptotic/necrotic BL6-10 cells was able to more powerfully 
stimulate allogeneic T-cell proliferation in vitro than vaccination with DCs pulsed with 
tumor peptide, and induce strong protective immunity against BL6-10 tumor challenge in 
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animal models (48). The vaccinations of necrotic or apoptotic tumor cell-loaded DCs had 
been studied in melanoma cells (42), leukemia cells (49) and squamous cell carcinoma 
(50) in animal models. All of these vaccines can significantly suppress tumor growth and 
appear to offer new strategies in DC cancer vaccines. 
1.5.4 Transgenic DC vaccines 
In animal models, vaccination with DCs pulsed with tumor peptides, lysates, mRNA or 
loaded with apoptotic/ necrotic tumor cells induce significant antitumor CTL responses 
and antitumor immunity. However, the results from early clinical trials pointed to a need 
for an additional improvement of DC-based vaccines because of the difficulty in 
preparation of such materials from human solid tumors. The transgenic DC vaccine is a 
new strategy that can overcome these technical difficulties. The target genes transferred 
into the DCs fall into two categories, TAAs and immunomodulatory proteins, such as 
cytokines or costimulatory molecules. Among the many methods that have been used to 
introduce genes into DCs, the adenovirus (AdV) vector was known to be a good 
candidate due to  high infection efficiency and the low risk associated with mutagenesis 
insertions.  
1.5.4.1 DCs Engineered to Express Tumor-associated Antigens 
DCs engineered to express tumor-associated antigens have several advantages over DCs 
pulsed with tumor antigen proteins and peptides. First, DCs engineered to express TAAs 
are more sensitive to the immunologic relevance of individual cancer-specific peptides as 
long as the molecules transduced into the DCs are immunogenic.  Second, the tumor 
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proteins that are synthesized within the DCs will permit specific antigen presentation to T 
cells for longer periods without the breakdown of the peptide/MHC complex (pMHC). It 
has been reported that DCs engineered to express TAAs have a more potent ability to 
prime the antitumor immune response in animal models than the DCs pulsed with tumor 
antigen proteins both in vitro and in vivo (51). Third, DCs engineered to express TAAs 
can generate CD8+ T cell responses against multiple class-I restricted epitopes within the 
antigens, resulting in a wide-ranging antitumor response (52). It has been demonstrated 
that vaccination using engineered DCs enhanced antitumor immunity via activation of 
CD8+ T cells (53). MART-1 (54), gp100 (55), p53 (56) and MUC-1 (51) have been used 
to transfect murine and/or human DCs to induce tumor antigen-specific immune 
responses.  
HER-2/neu (HER2 or c-erb-B2) antigen represents an ideal therapeutic target for breast 
cancer. It is commonly amplified and/or overexpressed in breast cancer, ovarian cancer 
and lung caner in humans. Y Chen et al have reported that genetic immunization using 
DCs transduced ex vivo with an adenovirus expressing the ErbB-2/neu gene (AdNeuTK) 
can induce protective and therapeutic immunity against a breast tumor cell line over-
expressing ErbB-2/neu (57). Moreover, vaccination with DC/AdNeuTK can cure mice 
with established tumors. This therapeutic effect is enhanced by co-transduction of the 
DCs with AdV vector encoding murine IL-12 (AdmIL-12) (57). Our lab has reported that 
the use of fiber-modified AdVneu-transduced DCs increased neu expression compared to 
non-modified AdVneu-transduced DCs. Fiber-modified DCneu showed up-regulation of 
MHC II, co-stimulatory, adhesion molecules as well as pro-inflammatory cytokines, 
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stimulated a higher percentage of HER-2/neu-specific CD8+ T cells, a stronger neu-
specific CTL response, and a much stronger T helper type I (Th1)/ T helper type II (Th2) 
mixed response than non-modified DCneu.  Moreover, in parental FVB/N and FVB/neuN 
Tg mice, vaccination with fiber-modified DCneu induced more efficient protective 
immunity than DCneu (58). In the treatment of breast cancers, the fiber-modified DC 
vaccine induced stronger anti-HER-2/neu immune response, because the fiber 
modification increases ex vivo trsnsfection efficiency. 
1.5.4.2 DCs engineered to express immunomodulatory molecules 
As mentioned above, DCs engineered to express TAAs are more effective than those 
simply pulsed with tumor peptides. However, it is difficult to choose appropriate tumor 
antigens as DC transduction candidates.  To augment the ability of DCs to stimulate a 
strong antitumor immunity, some immunomodulatory proteins such as cytokines and 
chemokines have been transducted into DCs. Engineered DCs expressing a T cell 
stimulatory cytokine can improve the treatment of tumor cells on the condition that the 
sources of TAAs are available. Additionally, compared to modified tumor cells, modified 
DCs can provide more potent vaccines because the DCs are professional APCs and can 
stimulate T cell antitumor activity. It has been demonstrated that immunomodulatory 
gene-modified DCs expressing some immune stimulatory cytokines or chemokines have 
been used as DC-based vaccines for cancer in animal models and induce stronger 
antitumor activity. 
   14
GM-CSF is an essential growth and differentiation factor for DCs in culture. It has been 
reported that administration of GM-CSF in vivo augments primary immune responses 
(59). Therefore, GM-CSF may be an ideal candidate to enhance the effectiveness of DC-
based vaccines. Clara Curiel-Lewandrowski et al reported that GM-CSF-transfected bone 
marrow derived dendritic cells (BM-DCs) displayed high level expression of MHC and 
costimulatory molecules. These engineered DC showed a high alloantigen or peptide 
antigen-presenting capacity in vitro. Moreover, the result of in vivo immunizations 
showed GM-CSF-transfected BM-DCs increase their Ag-presenting capacity and 
antitumor immunity, which was correlated with a better migratory capacity (60). 
IL-12 is naturally secreted by DCs (61), macrophages and human B-lymphoblastoid 
cells in response to antigenic stimulation. It enhances NK cell and CTL activities, plays a 
key role in the induction of Th1-type immune responses including IFN-γ production (62) 
and has IFN-γ/IFN-inducible protein 10-dependent anti-angiogenic effects (63, 64). 
Intratumoral (i.t.) injection with retrovirus IL-12 gene-modified BM-DCs could 
significantly suppress the growth of established tumors and induce a strong antitumor T-
cell response (65). 
IL-7 is a hematopoietic growth factor produced by the stromal cells of the red marrow 
and thymus. It plays an important role in proliferation during certain stages of B-cell 
maturation, T and NK cell survival, development and homeostasis. It has been reported 
that i.t. injection of adenoviral IL-7-transduced dendritic cells (DCAdVIL-7) resulted in 
complete tumor regression in two murine lung cancer models. Moreover, after complete 
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tumor eradication, those mice treated with DC-AdVIL-7 showed significantly greater 
release of splenocyte GM-CSF and IFN-γ (66). 
In our lab, we have also researched the possibility of inducing antitumor immunity 
using engineered DCs that can express Fms-like tyrosine kinase 3 ligand (Flt3L) (67), 
TNF-α (68) or co-stimulatory molecule 40 ligand (CD40L) (69). 
Flt3L is a regulator of hematopoietic cell development. It can drive DC development 
along both the lymphoid and myeloid developmental pathways from Flt3+ progenitors to 
Flt3+ DCs (70). Flt3L plays an important role in the expansion of both DCs (71) and NK 
cells (72, 73).  Our data showed that AdVFlt3L infection enhances cytokine (IL-1β) and 
chemokine (MIP-1α, MIP-1β, Interferon-y-inducible protein (IP)-10, monocyte 
chemotactic protein (MCP)-1 and MIP-2) expression, but not maturation of DCs. 
AdVFlt3L infection also stimulated adenovirus Flt3L gene-modified BM-DC (DCFlt3L) 
proliferation in vitro and induced their migration toward regional lymph nodes in vivo. It 
has also been demonstrated that DCFlt3L cells were able to stimulate a type 1 immune 
response comprising CD4+ Th1 and CD8+ Tc1 activation and induce the enhanced tumor-
specific cytotoxic T lymphocyte (CTL) and non-specific NK responses, compared to 
control virus-infected DCs (DCpLpA) and un-infected DCs. Vaccinations with Mut1-
pulsed DCs, DCpLpA and DCFlt3L protected mice from a low dose (0.5 × 105) challenge of 
3LL tumor cells. However, only vaccination with the Mut1-pulsed DCFlt3L was able to 
protect 63% (6/8) mice from a high dose (3 × 105) challenge of 3LL tumor cells. 
Therefore, vaccination with Mut1-pulsed DCFlt3L cells induced enhanced antitumor 
immunity in vivo, even against a high dose of  3LL tumor cells (67).  
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TNF-α is a multifunctional, immunoregulatory cytokine with a broad spectrum of 
activities, including induction of CD8+ T cell proliferation (74) and cytotoxicity (75), and 
provision of costimulatory survival signals for CD8+ T cells (76). In addition, it also can 
stimulate DC maturation (77), reduce/counteract IL-10-mediated DC inhibition (78), and 
inhibit the suppressive function of CD4+CD25+ regulatory T (Treg) cells by down-
regulation of fork-head/winged helix transcription factor (FoxP3) expression (79).  Our 
data show that DCs infected with recombinant adenovirus AdVTNFα (DCTNFα) displayed a 
greater maturation than control DCs cultured in exogenous TNF-α. DCTNFα up-regulated 
expression of pro-inflammatory cytokines (e.g. IL-1β and IL-18), chemokines (e.g. INF-
γ-inducible protein-10 and MIP-1β), the CC chemokine receptor CCR7, and 
immunologically important cell surface molecules (CD40, CD86 and ICAM-1). These 
transgenic DCs stimulated stronger allogenic T-cell responses in vitro and T-cell 
activation in vivo, displayed enhanced chemotactic responses to the MIP-3β in vitro, and 
trafficked into the draining lymph nodes more efficiently than the control DCs. 
Vaccination of mice with Mut1 peptide-pulsed DCTNFα induced more efficient in vitro 
Mut1-specific CD8+ cytotoxic T-cell responses and stimulated stronger anti-solid tumor 
immunity in vivo than control DCs cultured in exogenous TNF-α (68). Moreover, our 
data also show that vaccination with DCTNF-α cells pulsed with the OVA I peptide can 
reduce growth of the small (3–4 mm in diameter), but not large (6–8 mm in diameter), 
established MO4 (melanoma cell line) tumors. However, the large MO4 tumors in 3 out 
of 8 (38%) mice were eliminated through treatment with a combination of AdVTNF-α-
mediated gene therapy and TNF-α-gene-engineered DCTNF-α vaccination. This indicates 
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that the combined immunotherapy strategy is much more efficient in curing well 
established tumors than mono-therapy with a DC vaccine alone (80). 
CD40L, a 33-kDa type II membrane protein, is a member of the tumor necrosis factor 
(TNF) gene family that is expressed on activated CD4+ T cells (81, 82). The receptor for 
CD40L, CD40, is expressed on DCs. The CD40–CD40L interaction has been reported to 
be essential for activation of DCs via stimulation by CD4+ Th cells, with up-regulated 
expression of costimulatory CD80 molecule and ICAM-1 and secretion of IL-12, which 
can trigger CD8+ CTL responses (83, 84). Our data show that infection of DCs with 
recombinant adenovirus AdVCD40L resulted in activation of DCs with up-regulated 
expression of proinflammatory cytokines (IL-1β and IL -12), chemokines (IP -10, and 
MIP-1α), and immunologically important cell surface molecules (CD54, CD80, and 
CD86). Our data also demonstrate that DCs infected with AdVCD40L (DCCD40L) are able to 
stimulate enhanced allogeneic T- cell proliferation and Mut1- specific CD8+ CTL 
responses in vitro. Mut1 peptide-pulsed control virus–infected DC (DCpLpA), could only 
protect mice from a low dose challenge of 3LL tumor cells. However, vaccination with 
Mut1 peptide-pulsed AdVCD40L–infected DCCD40L induced a stronger antitumor immunity 
in vivo and protected mouse completely from challenge of both low and high doses of  
3LL tumor cells (69). 
Chemokines are a family of small cytokines secreted by some cells. The major role of 
chemokines is to act as a chemo-attractants to guide the migration of cells. In the immune 
system, chemokines may enhance the ability of DCs interacting with T cells. Chemokines 
play an integral role in the initiation of specific immune responses (85). Since DCs 
   18
express some chemokine receptors (86, 87), chemokines participate in the migration and 
recruitment of DCs (88, 89). Therefore, the genetic modification of DCs with chemokines 
can increase their antitumor immunity.  
 Lymphotactin (Lptn), a C chemokine, specifically attracts both NK cells and T cells in 
vivo (90, 91). Adenoviral Lptn -transduced dendritic cells (DCLptn) have been shown to 
induce a strong protective and therapeutic antitumor immunity. Immunization with a low 
dose (1×104) of Mut1 peptide-pulsed DCs induced a weak CTL activity, whereas the 
same amount of Mut1 peptide-pulsed DCLptn greatly increased specific CTL against 3LL 
tumor cells. Vaccination with 1×104 peptide-pulsed DCLptn could completely protect mice 
from 5×105 3LL tumor cell challenge, but the peptide-pulsed DC could not. Moreover, 
the pulmonary metastases of mice bearing 3LL tumor were significantly reduced with 
treatment of 1×104 Mut1 peptide-pulsed DCLptn, whereas the same low dose of Mut1 
peptide-pulsed DCs had no obvious therapeutic effects (92). 
Secondary lymphoid tissue chemokine (SLC), a CC chemokine, is able to recruit both 
DCs and naïve T cells via the CCR7 receptor found on both cell types (93, 94). Based on 
this, SLC is believed to play an important role in the initiation of an immune response by 
promoting the interaction of naïve T cells and the antigen that DCs present in the lymph 
node. Christopher J. Kirk et al reported that i.t. injection of SLC-expressing DCs (DCSLC) 
more strongly inhibits tumor growth than either control DCs or SLC alone. Distant site 
immunization of tumor bearing mice with tumor lysate pulsed DCSLC can stimulate an 
antitumor response whereas control DCs could not. They also found that subcutaneous 
(s.c). injection of lysate-pulsed DCSLC promoted the migration of T cells to the 
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immunization site. This report demonstrates that SLC expression by DCs can induce 
antitumor responses and enhance antitumor immunity (95). 
1.5.5 Problems in DC-based Vaccine 
In recent years, many key confounding issues with DC-based vaccines have been 
identified, which will ultimately lead to improving the feasibility and efficacy of the 
approach in years to come. These key problems arise mainly because of the specific 
characteristics of solid tumors that can evade both innate and adaptive immunity, such as: 
(i) tumor-induced T cell apoptosis by expression of FasL (96); (ii) prevention of T cells 
infiltration by tumor neovasculatures (97); (iii) lack of Th responses (98); and (iv) 
immune suppression related to tumoral IL-10 expression (99, 100)(28, 29) and 
recruitment of  Treg cells (101, 102).  
Because of these problems, the function of tumor specific T cells is limited by local 
factors within the tumor milieu. Therefore, modulation of this milieu may overcome 
tumor resistance to immunotherapy. By understanding the mechanisms of cancer cell 
immune-escape, it may be possible to design rational approaches to engineered DC-based 
therapies to target immunosuppression or prolong the survival of activated tumor specific 
T cells in an attempt to cure cancer effectively.  
1.5.5.1 Interlukin-10 (IL-10) and regulatory T cells (Treg) 
Within the tumor milieu, tumor cells and surrounding host stromal cells can secret 
immunosuppressive molecules, such as transforming growth factor-β (TGF- β), IL-10, 
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prostaglandin E2, and vascular endothelial growth factor (VEGF). Tumor-associated DCs 
usually have a low allostimulatory capacity, particularly if isolated from the progressing 
metastatic lesions, such as in malignant melanoma, or from blood, such as in patients 
with advanced breast cancer. By releasing cytokines such as IL-10, macrophage colony 
stimulating factor (M-CSF), and VEGF, tumors can prevent differentiation and function 
of APCs (103). Moreover, the suppressive tumor environment is also controlled by some 
immunosuppressive cells, such as Treg cells (104). Treg cells, as the professional 
immune suppressor cells, have been frequently found inside tumors and result in tumor 
escape from activated lymphocytes. Immune-suppression is related to tumoral IL-10 
expression and recruitment of Treg cells. 
IL-10 has been identified as a key immunomodulatory cytokine that is able to mediate 
immunosuppressive effects in the immune system. It plays a central role in maintaining 
the proper balance between protective immunity against infections/tumors and limiting 
proinflammatory responses to self-antigens. It inhibits CD4+ T cell proliferation and 
reduces DC immunogenicity, with down-regulated expression of MHC II, ICAM-1 and 
CD80. IL-10 leads to the formation of T-cell anergy (105) and induces Treg cells that 
suppress antigen-specific T-cell responses (101, 106). The immunosuppressive level of 
IL-10 can be detected in tumor cell cultures of many human tumors (99, 107). It has been 
reported that tumor-induced IL-10 inhibit tumor-specific CD8+ CTL cytotoxicity, 
resulting in the suppression of antitumor immunity and inhibition of protective immunity 
against the tumor (108). IL-10 also can impair the ability of DCs to stimulate CD4+ T cell 
responses, indicating that this cytokine is capable of  blocking tumor-specific Th1 
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responses (100). Moreover, IL-10 supports tumor growth by inhibition of macrophage 
function and induction of tumor and vascular cell proliferation in animal tumor models 
(109, 110). In the clinic, the level of IL-10 detected in the serum of patients becomes a 
negative indicator for clinical outcome of cancer therapy (111, 112). Therefore, T-cell 
suppression derived from tumor-secreted IL-10 becomes one of the major barriers to T-
cell immunotherapy of tumors. 
CD4+ Th cells had been grouped into Th1 (IFN-γ producing cells that respond to 
intracellular pathogens), Th2 (IL-4-, IL-5- and IL-13-producing cells that respond to 
parasitic infections), Th17 cells (related to the development of autoimmune diseases) 
(113) and Treg cell (the suppressive T cells) (114) subsets. The third and the fourth 
subsets of Th cells, Th17 cells and Treg cells have emerged in the last few years. Both 
TGF-β and IL-6 can cause naïve T cells to differentiate into Th17 cells, but TGF-β alone 
guides naïve CD4+ cells toward the suppressor Treg group (115, 116).  Treg cells are 
responsible for inducing and maintaining peripheral tolerance (117). Treg cells have been 
associated with human tumors, and increased numbers of Treg cells have been reported in 
the blood and tumors of patients with various cancers (117). The induction of Treg cells 
is relevant to a number of tumor environmental factors, such as VEGF, IL-10, TGF-β, 
and indoleamine 2, 3-dioxygenase (IDO). Treg cells can inhibit tumor-specific cellular 
immune responses in a variety of ways. Treg cells (CD4+CD25+) expressing the IL-2 
receptor, CD25, uptake IL-2 in the tumor microenvironment. IL-2 is not necessary to 
efficiently activate Treg cells, but is needed during suppression of responder cells, as 
specific blocking of the IL-2 receptor on Treg cells leads to a complete loss of regulatory 
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activity. In addition, IL-2 primes Treg cells to produce suppressive cytokine IL-10 upon 
re-stimulation (118).  Human Treg cells are capable of directly killing T cells and APCs 
via the perforin or granzyme B pathways (119). CTLA-4+ Treg cells can induce IDO 
expression in APCs, which can suppress T cell activation by depleting tryptophan (120). 
Treg cells can release IL-10 and TGF-β in vivo, and they directly inhibit T cell activation 
and suppress APC function by inhibiting the expression of MHC molecules, CD80, and 
CD86 and the production of IL-12 (117). Treg cells also induce B7-H4, a molecule of the 
B7 family and expression on APCs, which inhibit T cell activation. In addition, in a 
murine system, Treg cells were able to trigger high levels of IL-10 production by APCs, 
which up-regulated B7-H4 and induce an immunosuppressive response (121-124). Thus, 
Treg cells may inhibit TAA-specific immunity both directly and indirectly via APCs. 
1.5.5.2 Short Lifespan of DC-activated CD8+ T cells 
The in vivo CD8+ T cell responses include three main phases (125): (i) a proliferation 
phase of growth and differentiation of naive CD8+ T cells into effector T cells, (ii) a 
contraction phase of transition between the large population of  effector T cells to a 
smaller population (≈5-10%) of  Tm cells (126), and (iii) the memory phase of long-
term maintenance of  memory T (Tm) cells in the host. The DC vaccine- activated CD8+ 
T cells undergo a similar contraction phase of high-level activation-induced cell death 
(AICD). If most of the activated CD8+ T cells die quickly due to the AICD via apoptosis, 
the therapeutic efficacy of DC-based immune therapy is greatly limited. Therefore, a 
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critically important issue in DC-based therapy is how to promote increased survival of 
activated T cells. 
1.5.5.3 The Solid Tumor Environment Inhibit T Cell infiltration 
In clinical trials, scientists found that immune therapy is still limited to treatment of 
early stage cancers, and that this therapy showed little therapeutic efficacy for large 
tumors. This is due to the solid tumor microenvironment, which inhibit the infiltration 
and activities of CTLs (127).  
It has been reported that there is high interstitial pressure within a solid tumor. Elevated 
interstitial pressure principally reduces the driving force for extravasations of fluid and 
macromolecules in tumors, and also leads to an experimentally verifiable, radially 
outward convection which opposes the inward diffusion. Therefore, it could become a 
physical barrier, resulting in poor penetration of cytokine and immune cells into tumors 
(128).   
In solid tumors, the expression of some factors that are related to T lymphocyte 
migration from blood to the tumor site is reduced or absent. In the antitumor response, 
when adhesion receptors such as L-selectin and the alpha 4β7 integrin on T lymphocytes 
bind to ligands expressed on the venular endothelium, the migration can occur. It has 
been reported that the ligands for L-selectin and alpha 4β7 were not expressed in 
endothelial venule of solid tumors, which inhibits lymphocytic infiltration to limit the 
efficiency of antitumor immunity (129). Vascular adhesion protein 1 (VAP-1) is also 
essential for T-cell adherence to, and migration across the endothelium (130). In solid 
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tumors, the level of VAP-1 was reduced (131). Thus, down-regulating the expression of 
VAP-1 in tumor vasculature can possibly impair the effectiveness of lymphocyte therapy. 
Vascular cell adhesion molecule (VCAM)-1/ ICAM-1 is another factor that causes 
lymphocyte adhesion to the tumor endothelium. They show low expression in solid 
tumors (132) and this low level of VCAM-1/ICAM-1 expression is related to the 
secretion of angiogenic molecules such as basic fibroblast growth factor (BFGF) (133, 
134). The characterization of the solid tumor microenvironment explains some of the 
failure observed with immune cell based therapy.  
1.6 Interlukin-6 (IL-6) 
Interlukin-6 (IL-6) is a pleotropic cytokine and is secreted by many different cells, 
including monocyte/macrophages, fibroblasts, endothelial cells, keratinocytes, mast cells, 
T cells, dendritic cells and many tumor cell lines (135). The events causing an 
inflammatory response can increase IL-6 secretion. The location of the IL-6 gene in the 
human gene is 7p21 (136) and the transcription of the IL-6 gene requires several 
transcription factors, including nuclear factor κB (NF-κB), CAAT/enhancer-binding 
protein (C/EPB) family members and activator protein 1 (AP-1) (137). Moreover, the IL-
6 promoter is inhibited by p53 and retinoblastoma (Rb) (138, 139). The molecular weight 
of IL-6 is between 21.5 and 28 kilo-dalton (Kd). 
1.6.1 IL-6 signaling Pathway  
The IL-6 receptor (IL-6R), as a member of the class I cytokine receptor family, contains 
ligand biding components (IL-6Rα) and signal transducing components (gp130) (140). 
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The IL-6Rα binds IL-6 directly and comprises two forms, a membrane-bound form and a 
soluble form (141). A homodimer of gp130, which is in the cell membrane, can not bind 
the IL-6, but plays an important role in the formation of a high-affinity IL-6 binding site 
and transduction of the IL-6 signal (142). Moreover, there is some soluble gp130 in 
human serum, but it is an antagonist of the IL-6/sIL-6Rα complex (143). IL-6 binding to 
a cell via the IL-6R (IL-6Rα/gp130 complex) triggers a series of events that leads to the 
activation of the Janus kinase (JAK)/ signal transducer and activator of transcription 
(STAT3) pathway or the activation of mitogen-activated protein kinase (MAPK) pathway, 
switching on target genes (144). 
1.6.2 The Function of IL-6 in Immune System 
A large number of cells in the immune system are capable of IL-6 synthesis. IL-6 plays 
a key role in the progression from the initial innate immune response to infection to an 
adaptive immune response (145). IL-6 can activate the JAK/STAT3 pathway. The 
activated STAT3 dimerizes via phosphorylation and travels to the nucleus, triggering a 
transcriptional program (144). The function of this program is to promote growth and 
differentiation and prevent apoptosis (146). It has been reported that the IL-6 exerts an 
antiapoptotic effect on a wide variety of cells, including plasma cells, liver cells, neurons, 
master cells, endothelial cells and pancreatic β cells (147-151). In particular, it plays a 
central role in determining the number of memory and/or effector CD4+ T cells in 
response to immunization over extended periods (152). Moreover, it has been determined 
that IL-6 inhibits apoptosis of activation-induced cell death of T cells through reduction 
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of the level of T cell receptor (TCR)/CD3-induced apoptosis and expression of Fas/ Fas 
ligand (FasL). Furthermore, in this process,  IL-6 can not decrease IL-2 induced 
activation of T cells (153).  
Moreover, as mentioned in Section 5.5.1, Treg cells inhibit TAA-specific immunity 
both directly and indirectly through APCs. IL-6 can inhibit the formation of CD4+ 25+ 
Treg cells in the immune system (115, 116). Therefore, IL-6 may increase T-cell 
activation and overcome the immune-suppression that is induced through tumoral IL-10 
expression and Treg cells. IL-6 may be a candidate for an engineered-cancer vaccine. 
1.7 Adenoviruses (AdVs)  
In the 1953, adenovirus (AdV) was first discovered and the features have since been 
broadly characterized. Several of these features have made adenovirus an excellent 
vehicle for gene transfer and transgene expression in mammalian cells. 
1.7.1 Adenovirus Properties 
AdV have been isolated from several avian and mammalian cells. Of these, more than 
40 known serotypes of human AdV have been divided into 6 subgroups (A to F), 
according to their oncogenic potential in rodents and their similarity in DNA sequences 
(154). The serotype 2 and the serotype 5 of subgroup C have been developed as vectors 
for gene delivery.  
AdV, a non-enveloped icosahedral nucleocapsid, is composed of 240 hexons and 12 
pentons (155). The penton subunits and the hexons build up the twelve vertices of the 
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icosahedrons and the face of the icosahedral capsid, respectively. There is fiber protein 
projecting from each of the penton, and at the end of the each fiber, there is a globular tip 
named the knob domain.  The AdV contains a linear double stranded DNA genome, the 
size of which is between 30 to 40 kb. The serotype 5 genome is 35,935 base pairs (bp) 
(156). 
AdV transcription consists of two phases, early and late, which happen before and after 
viral DNA replication, respectively. Based on these, the AdV genome is divided into two 
kinds of genes, early transcribed regions( E1, E2, E3, E4) and late transcribed regions (L1, 
L2, L3, L4, L5). The early transcribed regions play an important role in adenoviral gene 
transcription, DNA replication, host immune-suppression and inhibition of host cell 
apoptosis. The E1 gene is essential for the assembly of infectious virus particles. The 
gene products of the E2 region are related to viral DNA replication and the ensuing 
transcription of late genes. Moreover, the proteins encoded by E4 are involved in the 
metabolism of viral messenger RNA, provide functions that promote viral DNA 
replication and shut-off of host protein synthesis. However, the E3 proteins are involved 
in evading host immunity, which is not essential for viral growth in vitro. After the 
replication of viral DNA, the expression of the early genes is stopped and the late genes 
start transcribing via the major late promoter. The late genes encode for the formation of 
the virion’s structural proteins (157). 
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1.7.2 Adenovirus Infection 
For the subgroup C AdV, including serotypes 5 and 2 AdV,  during the process of Ad 
infection, the first step is the binding of AdV on target cells, which requires two specific 
cell-surface receptors, “Coxsackie virus and Adenovirus receptor” (CAR) and αvβ3 or 
αvβ5 integrins. First, the knob domain located at the end of the AdV fiber binds to the 
CAR on the target cell (158, 159). After the attachment step, interaction between the 
arginine-guanine-aspartate (RGD) modif located on the penton base and the αvβ3 or αvβ5 
integrins leads to the internalization of the virus through endocytosis (160).  It has been 
reported that the DCs do not express CAR but high levels of αvβ3 or αvβ5 integrins (161-
163). To improve infection of AdV into CAR-negative (or low) cell lines, an RGD 
peptide motif was incorporated into H1 loop of the AdV knob domain. It has been 
suggested that the efficiency of DC transduction by fiber-modified AdV is enhanced 
about 10-fold in vitro and there is a 5-10 fold increase of transgene expression in the 
fiber-modified AdV transduced DCs (164-166). The fiber-modified AdV vector targeted 
DCs may be practical in the development of AdV-based vaccines. 
Once entering the target cell, the virus releases the endosome into the cytosol via penton 
base mediating lysis of the endosomal membrane. Then, the viral DNA enters to the 
nucleus and transcription begins. In the nucleus of the infected cell, transcription, 
replication and viral packaging will occur.  
   29
1.7.3 Recombinant Adenovirus 
  Adenovirus has been adapted to make it a versatile tool for gene delivery and gene 
therapy. Recombinant adenovirus (rAdV) has had the E1 and E3 domains deleted. The 
E1 gene deletion prevents the rAdV from replicating itself and therefore no cell lysis 
occurs. The E1 gene is complemented by an adenovirus packaging cell line (e.g. AD-293). 
The E3 gene is dispensable for viral growth. These two deletions also allow for an 
additional 7.5 kb of foreign DNA (167).  
  Compared with the other vectors, rAdV vector has the following advantages: (i) AdV 
can infect a wide range of host species in vitro and in vivo and express human and non-
human proteins. AdV also has low pathogenicity in human and no significant side effects 
(168). (ii) AdV can infect and express genes in both replicative and non-replicative cells, 
however, the retrovirus can only infect replicative cells. (iii) AdV is relatively stable and 
can be obtained in high titer (e.g. 1011-1012 plaque-forming units (PFU)/ml). (iv) AdV is 
capable of accepting large-sized gene (7.5kb) insert and expressing multiple genes in the 
same cell line or tissue. (v) AdV does not integrate into the host chromosome and the 
inserted genes are expressed epichromosomally (169). This prevents the possibility of 
disturbing the host cellular genes and does not cause the host gene to be mutated. (vi) 
AdV can propagate in suspension cultures, allowing for easy scale-up of production (59). 
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Chapter 2 
HYPOTHESIS 
It is recognized that dendritic cells (DCs) play an important role in stimulating 
antitumor immunity. Based on these powerful important roles of DCs, DC-based 
vaccines have been proposed as a treatment modality for cancer. In animal models, 
vaccination with DCs pulsed with tumor peptides, lysates, mRNA or pulsed with 
apoptotic/ necrotic tumor cells, or DCs engineered with transgenes, including tumor-
associated antigens (TAAs) and immunomodulatory proteins, could induce significant 
antitumor cytotoxic T lymphocyte (CTL) responses and antitumor immunity. However, 
in clinical trials, only a small part of patients have responded to these DC-based vaccines 
(170, 171). In recent years, some problems with DC-based vaccines have been identified, 
in addressing which will eventually lead to improve the feasibility and efficacy of the 
approach in years to come. Among these problems, the most significant include (i) 
immune suppression related to tumoral interleukin (IL)-10 expression (99, 100) and 
recruitment of regulatory T (Treg) cells (101, 102); and (ii) the short life span of activated 
T cells due to high-level of activation-induced cell death (AICD). It is shown that the IL-
6 cytokine can inhibit CD4+CD25+ Treg cell-mediated immune suppression (115, 116) 
and enhance the activated T cell survival via suppression of AICD without interfering 
with the process of T cell activation (153).  The AdV vector is known to be a good 
candidate to introduce gene into DCs and could play a beneficial role in the development 
of this treatment. 
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With this knowledge in mind, we hypothesize that: (i) DCs infected with the IL-6 gene 
via adenovirus can secrete transgenic IL-6; (ii) CD8+ CTL cells activated by the IL-6 
infected DCs may counteract Treg-induced immune suppression; (iii) CD8+ CTL cells 
activated by IL-6 infected DCs may show prolonged survival. 
Therefore, IL-6 infected DC-activated CD8+ CTL, which have prolonged survival and 
enhanced counteraction of Treg-mediated immune suppression, could greatly increase 
immunogenicity, and lead to efficient CD8+ CTL responses and antitumor immunity. 
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Chapter 3 
OBJECTIVES 
The aims of this thesis were to study (i) the effects of IL-6 in DC-based vaccines and (ii) 
the immune mechanism of these effects induced by IL-6. To reach our aims, we plan to (i) 
construct the adenovirus (AdV) with an IL-6 transgene insertion for use as a vector to 
introduce the IL-6 gene into DCs, (ii) generate the IL-6 transgene-engineered DC vaccine 
expressing IL-6, (iii) assess weather the IL-6 engineered-DC vaccine can enhance CD8+ 
CTL responses and antitumor immunity in a BL6-10OVA animal tumor model, and (iv) 
study the immune mechanism underlying the results of the IL-6 engineered-DC vaccine.   
3.1 Construct AdV Vector 
To transfer the IL-6 gene to DCs, we will construct a fiber-modified AdV vector with an 
IL-6 gene insert using the AdEasy system. Since DCs do not express ‘Coxsackie virus 
and Adenovirus receptor’ (CAR) but rather high level of integrin (161-163), the fiber-
modified AdV vector can enhance the infection of DCs by the AdV. 
3.2 Generate the IL-6 Transgene-engineered DC 
For studying the effect of DC vaccine secreting IL-6 cytokine, we will transfect bone-
marrow derived DCs with AdV containing IL-6 gene insert. These AdV-mediated IL-6 
transgene engineered-DCs should express the high level of IL-6. 
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3.3 Assessing Weather the IL-6 Engineered-DC Vaccine can Enhance CD8+ CTL 
Responses and Antitumor Immunity  
After being pulsed with ovalbumin (OVA) antigen, IL-6 infected DCs become the IL-6 
engineered-DC vaccine. The effect of IL-6 engineered DC-based cancer vaccine will be 
examined by analyzing (i) the effect of AdVIL-6 infection on DC phenotype and function, 
and (ii) the antitumor effect of this vaccine in a BL6-10OVA animal tumor model. 
3.4 Elucidating the Immune Mechanism underlying the Results of IL-6 Engineered-
DC Vaccine  
To explore the possible mechanism underlying the effects induced by the IL-6 
engineered-DC vaccine, we will (i) generate the IL-6 engineered DC-activated CD8+ T 
cells in vitro, (ii) assess the phenotypic characterization of these T cells by flow 
cytometry, (iii) determine weather these T cells show prolonged survival, and (iv) 
analyze the therapeutic effect of these T cells in mice bearing solid EG7 tumor. 
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Chapter 4 
MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Reagents and Suppliers 
In the table 4.1, some reagents used in the experiments presented in this thesis are 
displayed.  All of the reagents used are of the molecular biology or research grade. In the 
table 4.2, all of the commercially available kits used in this study are displayed. 
 
Table 4.1:  List of reagents and suppliers 
 
Reagent Supplier Name 
Agar Invitrogen 
Agarose Invitrogen 
Alkaline phosphatase New England Biolabs 
Ammonium chloride EM Sciences 
Ampicillin Sigma 
Bacto-tryptone BD Bioscience 
BSA Sigma 
Calcium chloride Sigma 
Cesium chloride Sigma 
CFSE Molecular Probes 
Chloroform EM Sciences 
RPMI 1640 Invitrogen 
DMEM Invitrogen 
AIM-V medium Invitrogen 
   35
Reagent Supplier Name 
DMSO Sigma 
dNTP mix (dATP, dCTP, dGTP, dTTP) Invitrogen 
Electroporation cuvette (0.2cm, 0.4 cm gap) Bio-Rad 
EMEM Invitrogen 
Ethanol EM Sciences 
Ethidium bromide Sigma 
FBS Hyclone 
HEPES Invitrogen 
Formalin EM Sciences 
Gentamicin Reagent Solution Invitrogen 
Glutaraldehyde Sigma 
Glycerol BDH Inc 
Glycine EM Sciences 
GM-CSF R&D Systems 
Hydrochloric acid EM Sciences 
IL-2 Peprotech 
IL-4 R&D Systems 
Isopropanol EM Sciences 
Kanamycin Sigma 
Lysozyme Sigma 
Magnesium chloride Sigma 
Methanol EM Sciences 
Non-fat dry milk Carnation 
PEG-8000 Sigma 
Phenol EM Sciences 
RNase Amersham Biosciences 
RPMI 1640  Invitrogen 
SDS Sigma/Bio-Rad 
Sodium acetate BDH Inc 
Sucrose BDH Inc 
Sulfuric Acid (H2SO4) BDH Inc 
T4 DNA ligase Invitrogen 
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Reagent Supplier Name 
Taq DNA polymerase Invitrogen 
TRIS EM Science 
Trypan Blue Stain  Invitrogen 
Trypsin/EDTA Invitrogen 
Tween 20 Bio-Rad 
X-gal Invitrogen 
Yeast Extract Difco 
β-mercaptoethanol Bio-Rad 
λDNA/HindIII marker Invitrogen 
φX174/HaeIII fragment marker  Invitrogen 
Ovalbumin (OVA) Sigma 
OVA I peptide  Sigma 
________________________________________________________________________
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________________________________________________________________________ 
Table 4.2:  Commercially available kits used in this study 
______________________________________________________________________________ 
Commercial Kits Supplier Name 
Superscript first strand synthesis for RT-PCR kit Invitrogen 
GenElute Agarose Spin column Sigma 
PE-labeled H-2Kb/OVA 257-264 tetramer Beckman-Coulter 
Plasmid Mini Kit Qiagen 
Qiaprep Spin Kit Qiagen 
Mouse IL-6 ELISA Set BD Bioscience 
TMB Substrate Kit BD Bioscience 
TA Cloning Kit Invitrogen 
Zero Blunt PCR cloning kit Invitrogen 
Nylon wool column C&A Scientific 
Anti-mouse CD4 (L3T4) paramagnetic beads  Invitrogen 
Cytofix/ CytoPerm Plus with GolgiPlug Kit BD Bioscience 
Slide-A-lyzer dialyzing cassette Pierce 
 
4.1.2 Antibodies 
A variety of Abs used in our study and their respective suppliers are listed in the table 
4.3.  These Abs were conjugated with either fluorescein isothiocyanate (FITC), 
phycoerythrin (PE) or biotin. 
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________________________________________________________________________ 
Table 4.3:  List of antibodies and respective suppliers 
 
Antibody Supplier 
Biotin conjugated anti-mouse MHC class ⅡIab  BD Bioscience 
Biotin conjugated anti-mouse CD11c BD Bioscience 
Biotin conjugated anti-mouse CD25 BD Bioscience 
Biotin conjugated anti-mouse CD40 BD Bioscience 
Biotin conjugated anti-mouse CD54 BD Bioscience 
FITC conjugated anti-mouse CD8   Beckman-Coulter 
Biotin conjugated anti-mouse CD8 BD Bioscience 
Biotin conjugated anti-mouse CD80 BD Bioscience 
Biotin conjugated anti-mouse CD69 BD Bioscience 
PE conjugated anti-mouse CD62 ligand 
(CD62L) 
BD Bioscience 
PE conjugated anti-mouse Fas ligand (FasL)  Blue Genes 
FITC conjugated anti-mouse Perforin  ALEXIS 
FITC conjugated streptavidin  BD Bioscience 
________________________________________________________________________ 
4.1.3 Cell Lines 
A murine dendritic cell line DC2.4 was obtained from K. Rock (Dana-Farber Cancer 
Institute, Boston, Mass) and cultured in RPMI 1640 medium (Invitrogen, Burlington, ON, 
Canada) supplemented with L-glutamine (2 mM), non-essential amino acids (100 μM), 2-
mercaptoethanol (2-ME, 50 μM), 1% (v/v) 4-(2-hydroxyethyl)-1-piperazine-1-
ethanesulfonic acid (HEPES; Invitrogen, Burlington, ON, Canada) and 10% (v/v) fetal 
bovine serum (FBS; Hyclone, Logan, UT). The mouse OVA-specific B16 melanoma cell 
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line BL6-10OVA was generated in our laboratory (172). The OVA transfected cell line 
EG7, which is derived from the mouse thymoma cell line EL4, was obtained from 
American Type Culture Collection (ATCC).  Both the BL6-10OVA and EG7 cell lines 
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen, 
Burlington, ON, Canada) containing 10% (v/v) FBS (Hyclone, Logan, UT) and G418 
(0.5mg/ml). The human embryonic kidney cell line 293 containing the adenoviral E1 
genes were purchased from Microbix (Toronto, ON, Canada) and cultured in Minimum 
Essential Medium containing Earle’s Salts (EMEM; Invitrogen, Burlington, ON, Canada) 
supplemented with 10% FBS. All of the media used also included 30 μg/ml gentamicin 
solution (Invitrogen, Burlington, ON, Canada). 
DC2.4, BL6-10OVA and 293 cell lines were adherent cell lines. The DC2.4 and BL6-
10OVA cell lines were passaged using Trypsin/ethylenediamine tetracetic acid (EDTA; 
Invitrogen, Burlington, ON, Canada) whereas the 293 cell line was passaged using a 1× 
citric saline solution [10% (w/v) KCl and 4.4% (w/v) sodium citrate].  All cell lines were 
cultured in a 37°C humidified CO2 incubator with a 5% CO2 atmosphere.  Trypan-Blue 
(Invitrogen, Burlington, ON, Canada) was used for cell counting on a haemocytometer. 
4.1.4 Animals 
The OVA-specific T cell receptor (TCR) transgenic OTI mice, having a transgenic 
Vα2Vβ5 TCR specific for the OVA257–264 epitope in context of H-2Kb (173), and naïve 
C57BL/6 (B6, CD45.2+) mice were obtained from the Jackson Laboratory (Bar Harbor, 
ME). All mice were approximately 4-6 weeks old and housed in the Saskatoon Cancer 
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Centre animal facility.  All animal experiments were carried out in accordance with the 
Canadian Council for Animal Care guidelines. 
4.1.5 Bacterial Cells 
DH5α E. coli and E. coli BJ5183 cells were used as the bacterial hosts for vector 
propagation and for homologous recombination in the construction of AdV vectors, 
respectively. E. coli BJ5183 cells were obtained from Stratagene (La Jolla, CA). Both of 
these bacteria were grown in medium containing Lauria-Bertani (LB) broth consisting of 
1.0% (w/v) tryptone (Voigt Global Distribution, Lawrence, KS), 0.5% (w/v) yeast extract 
(Voigt Global Distribution, Lawrence, KS) and 1.0% (w/v) NaCl complemented with the 
appropriate antibiotic such as ampicillin (100μg/ml) or kanamycin (50 μg/ml), depending 
on the vector, in a shaking incubator at 37°C.  For isolation of transformed bacterial cells, 
the cells were plated onto selective LB-agar plates, containing LB broth with 1.5% (w/v) 
agar complemented with the appropriate antibiotic, and incubated at 37°C overnight. 
4.2 Methods 
The routine molecular biology protocols used in our study were based upon Molecular 
Cloning: A Laboratory Manual by Sambrook and colleagues and Sambrook and Russel 
(174, 175). 
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4.2.1 RNA Methods 
4.2.1.1 RNA Isolation 
The RNA was isolated from the cell samples by using the RNeasy mini kit (Qiagen, 
Mississauga, ON, Canada) according to the manufacturer’s suggested protocol. Isolated 
RNA was re-suspended in RNase free distilled water and stored in liquid nitrogen until 
needed. The concentration and purity of the isolated RNA were measured by standard 
A260/A280 spectrophotometric readings. 
4.2.1.2 cDNA Synthesis and RT-PCR  
The isolated RNA was used as a template for the first-strand cDNA synthesis using the 
SuperScript First-strand Synthesis System for reverse transcriptase-polymerase chain 
reaction (RT-PCR) (Invitrogen, Burlington, ON, Canada) in accordance with the 
instructions provided by the manufacturer.  In brief, 5 μg of RNA was incubated in 20 
mM Tris-HCl (pH 8.4), 50 mM KCl, 5 mM MgCl2, 10 mM dithiothreitol (DTT), 0.5 mM 
of each dNTP, 0.5 μg Oligo(dT)12-18, 40 units of RNase inhibitor and 50 units 
SuperScript II reverse transcriptase enzyme, for a final volume of 20 μl.  To terminate the 
reaction, the sample was incubated at 42°C for 50 min followed by 70°C for 15 min.  The 
sample was then treated with 1 unit of RNase H to remove remaining RNA.  The cDNA 
samples were used either immediately for polymerase chain reaction (PCR) reactions or 
stored at -20°C for future use. 
   42
The PCR reactions were done in a volume of 100 μl containing the cDNA sample, 20 
mM Tris-HCl (pH 8.0), 20 mM KCl, 1.5 mM MgCl2, 1 mM deoxynucleotide 
triphosphate (dNTP) mix (dATP, dCTP, dGTP, dTTP), 10 ng of each primer and 2.5 
units of Taq polymerase (Invitrogen, Burlington, ON, Canada). As shown in the table 4.4, 
the PCR primers for the IL-6 gene and the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were designed based on the gene sequence obtained 
by GeneBank Accession number NM_031168 and NM_008084, using MacVector 
software, respectively. The level of GAPDH expression was used as a control reaction for 
RT-PCR samples. The PCR cycle included the initial DNA denaturing step at 94°C for 2-
5 min followed by 30 amplification cycles at 94°C for 30 sec, 60°C for 30 sec and 72°C 
for 30 sec followed with a final termination step for 7-10 min at 72°C.  One-tenth of the 
reaction volume was resolved by 1.5% agarose gel electrophoresis after PCR 
amplification. 
Table 4.4: RT-PCR primers 
 
Gene 
 
Template Forward and reverse primers 
IL-6 DC2.4 RNA 5’- ACCGC TATGA AGTTC CTCTC TGC -3’ 
5’- AGGCA TAACG CACTA GGTTT GC -3’ 
GAPDH DC2.4 RNA 5’- CAGGT TGTCT CCTGC GACTT -3’ 
5’- CTTGC TCAGT GTCCT TGCTG -3’ 
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4.2.2 DNA Methods 
4.2.2.1 Restriction Enzyme Digest 
The restriction enzymes used in this study were purchased from either GE Healthcare 
(Baie d'Urfé, Québec, Canada) or New England Biolabs (NEB, Pickering, ON, Canada). 
The restriction enzyme digestions were performed using at least 1μg DNA in 1× the final 
recommended buffer suggested by the manufacturer and at least 1 unit of the specified 
enzymes. For complete restriction enzyme digestion, the reactions were incubated at 
37°C for 1 hour. 
4.2.2.2 Agarose Gel Electrophoresis 
Agarose gels were casted using a GelHorizon 58 Apparatus of varying agarose 
concentrations ranging from 0.7% to 1.5% in Tris-acetate EDTA (TAE) buffer [40 mM 
Tris-acetate, 1 mM EDTA containing 1 μg/ml ethidium bromide (EtBR; Sigma, Oakville, 
ON, Canada)].  The sample products were loaded onto the gels with gel loading buffer 
[0.042% (w/v) bromophenol blue, 6.67% (w/v) sucrose] along with the DNA markers, 
λDNA/Hind III and φX174/Hae III fragment markers (Invitrogen, Burlington, ON, 
Canada).  Gel electrophoresis was performed between 90 to 110 V in TAE buffer for 
varying times to attain optimal resolution.  The gel was visualized by UV illumination 
using a gel documentation system (Bio-Rad, Mississauga, ON, Canada). 
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4.2.2.3 Purifying Linear DNA Fragments 
The GenElute Agarose spin columns (Sigma, Okaville, ON, Canada) were used to 
isolate and purify the linear DNA fragments from DNA agarose gels, according to the 
instructions provided by the manufacturer. Briefly, the spin column was pre-washed with 
100ul of 1× Tris EDTA (TE) (10mM tris, PH 8.0, with 1mM EDTA). The band of DNA 
fragment was then cut from the agarose gel, sliced into smaller pieces and placed onto the 
pre-washed spin column. The DNA solution was collected in a separate tube after 
centrifugation of column at maximum speed for 10 min. Following ethanol precipitation, 
the DNA pellet was re-suspended in distilled water or TE buffer, and then stored at -20°C 
until use.         
4.2.2.4 Ligation of IL-6 PCR Products with pCR2.1 Vector 
The ligation of IL-6 PCR products with pCR2.1 vector was performed using the TA 
cloning Kit (Invitrogen, Burlington, ON, Canada). The Taq polymerase has terminal 
transferase activity that adds a single deoxyadenosine (A) overhang to the 3’ ends of PCR 
products. The pCR2.1 vector supplied in the kit is linearized and has single 3’ 
deoxythymidine (T) overhangs. Therefore, it is possible to clone Taq-generated PCR 
products directly into a linearized cloning pCR2.1 vector. Ligations were performed 
using T4 DNA ligase overnight in a 14°C water bath. 
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4.2.2.5 Sequencing IL-6 PCR Products 
The RT-PCR products of IL-6 in TA vectors were sequenced with the M13 forward (-
20), 5’- GTAAA ACGAC GGCCA G -3’, and reverse, 5’- CAGGA AACAG CTATG 
AC -3’ primers, at the Plant Biotechnology Institute of the National Research Council of 
Canada in Saskatoon, Saskatchewan. 
4.2.2.6 Competent Cells and Transformation 
4.2.2.6.1 Competent Cell Preparation and Chemical Transformation 
Competent cells were prepared based on a standard method previously described by 
Chan et al (176).  Briefly, an overnight culture of bacterial cells were grown in LB 
medium until mid log-phase growth with an OD600 reading between 0.4-0.6, then spun 
down.  The cell pellet was washed twice with fresh 50 mM Calcium Chloride (CaCl) 10 
mM Tris-HCl (pH 8.0) and then re-suspended in the same solution.  Transformations 
were performed incubating 50-100 μl of competent cells with the DNA mixture on ice for 
30 min.  The sample was heat-shocked by quickly placing the sample in a 42°C water 
bath for 50 seconds, then immediately returning it to ice for 1 min.  To allow the bacteria 
to recover before plating the cells on selective LB-agar plates, SOC media [2% (w/v) 
bacto-tryptone, 0.5% (w/v) yeast-extract, 0.05% (w/v) NaCl, 20 mM glucose] was added 
and the sample was incubated at 37°C for 1 hour. When blue and white colony screening 
was needed, the selective LB-agar plates were supplemented with 50μg/ml X-gal 
(Invitrogen, Burlington, ON, Canada) and 0.1 nM isopropylthio-β-D- galactoside (ITPG; 
Invitrogen, Burlington, ON, Canada).  
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4.2.2.6.2 Electrocompetent Cell Preparation and Eletrotransformation 
Electrocompetent cells were prepared as previously described (175, 177).  The bacterial 
cells were grown overnight in selective LB broth. In the following morning, these 
bacterial cells were sub-cultured in fresh media until mid-log phase was reached with the 
OD600 reading between 0.4-0.6.  Bacterial cells were chilled then centrifuged at 1,000 × g 
in a JA-10 rotor (Beckman, Mississauga, ON, Canada).  After washing the sample twice, 
the sample was re-suspended in a 10% (v/v) glycerol in water solution and stored at -
80°C until required.  Both the bacterial cells and the DNA were placed into chilled 
electroporation cuvettes (0.2 cm gap; Bio-Rad, Mississauga, ON, Canada) and then 
electroporated using the conditions: 200 Ω (ohms), 2.5 kV and 25 μFD using a Gene 
Pulser with Pulse Controller (Bio-Rad, Mississauga, ON, Canada).  To allow the bacteria 
to recover before plating the cells onto selective LB-agar plates containing the 
appropriate antibiotic, LB media was added to the sample and incubated at 37°C for 1 
hour. 
4.2.2.7 Isolation of Plasmid DNA from Host Bacterial Cells 
4.2.2.7.1 Isolation of Plasmid DNA from Host Bacterial Cells (mini-prep) 
To screen colonies for positive transformants, a small scale plasmid preparation using 
an alkali lysis method was performed.  Isolated colonies were selected and cultured 
overnight in LB with the appropriate antibiotic. In the following morning, the cultured 
cells were re-suspended in 50 mM glucose, 10 mM EDTA, 25 mM Tris-HCl (pH 8.0), 2 
mg/ml lysozyme (Sigma, Oakville, ON, Canada), then lysed with a 200 mM NaOH, 1% 
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sodium dodecyl sulfate (SDS) solution followed by the addition of 3 M sodium acetate, 
pH 5.2. This method precipitated out the bacteria chromosomal DNA, cellular protein 
and debris. The supernatant was extracted twice with phenol:chloroform:isoamyl alcohol 
followed by an ethanol precipitation.  The precipitated DNA was re-suspended in TE (pH 
8.0) containing 40 μg/ml RNAse A.  DNA concentration was measured by standard 
A260/A280 spectrophotometric readings and visualized on agarose gels.   
4.2.2.7.2 Isolation of Plasmid DNA from Host Bacteria Cells (large scale) 
Bacterial cells were grown overnight in Terrific broth (TB) [1.2% (w/v) bacto-tryptone, 
2.4% (w/v) yeast-extract, 0.4% (v/v) glycerol, 17 mM KH2PO4 and 72 mM K2HPO4] in a 
shaking incubator at 37°C.  The sample was treated with the same solutions as the mini-
prep with the addition of an extra polyethylene glycol (PEG) purification step.  Finally, 
the purified DNA was re-suspended in TE (pH 8.0) or in sterile phosphate buffered saline 
(PBS) for use in infection. The concentration of the purified DNA was determined using 
standard A260/A280 spectrophotometric readings and visualized on agarose gels. 
4.2.3 AdV Methods 
4.2.3.1 AdV Vector Construction 
The vectors pShuttle-CMV and pAdEasy-1 were obtained from Dr. Lixin Zhang (John 
Hopkins/Sidney Kimmel) and Stratagene (La Jolla, CA), respectively. To increase the 
effect of AdV infection of DC, the fiber-modified adenoviral vector, AdV(RGD), was 
required.  The fiber gene was modified by inserting the arginine-guanine-aspartate (RGD) 
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motif into the viral HI loop and the fiber-modified adenoviral vector, AdV(RGD), was 
created using the AdEasy system (178) similar to the method described by Liu and 
colleagues (179) as described below.  
To create the fiber-modified vector, the pAdEasy-1 vector was digested with BamHI, 
resulting in 21.7- and 11.7-kb DNA fragments.  The 11.7-kb fragment was inserted into 
pCRBlunt vector, which is from Zero Blunt PCR cloning kit (Invitrogen, Burlington, ON, 
Canada), to generate pCR11.7 vector.  This pCR11.7 vector was digested with EcoRI, 
resulting in 9.3- and 5.6-kb DNA fragment.  The 9.3-kb fragment, consisting of the 
pCRBlunt backbone, underwent self-ligation, constructing pCR9.3 vector.  PCR 
amplification was utilized to replace sequences within the StuI-AflII sites of the fiber 
knob domain in pCR9.3 vector.  In the PCR, the sense primer 1 (5’- CAACA AAGGC 
CTTTA CTTGT TTACA GCTTC A -3’) and antisense primer 2 (5’- TGACA  TAGAG 
TACTG GTTTA GTTTT GTCTC CGTTT AAG -3’) were utilized to amplify a 680-base 
pair (bp) P1+P2 fragment (nucleotides 31950-32630 of the Ad5 genome), while the sense 
primer 3 (5’- ACTAA ACCAG TACTC TATGT CATTT TCATG GGACT GGT -3’) 
and the antisense primer 4 (5’- TGGAC AGCGA CATGA ACTTT AAGTG AGCTG -3’) 
were utilized to amplify a 435-bp P3+P4 fragment (nucleotides 32690-33125 of the Ad5 
genome).  The P1+P2 and P3+P4 fragments were gel purified, mixed, and joined by PCR 
using P1 and P4, resulting in a 1.1-kb fragment.  This fragment contains part of the knob 
sequence of Ad5 with AflII (nucleotide 31950) and StuI (nucleotide 33125) sites.  A 
deletion was created from 32631-32689 removing amino-acid residues VTLTI TLNGT 
QETGD TTPSA, and incorporated a single mutation from T to A to create a ScaI site in 
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the HI loop. Plasmid pCR9.3(AS) was formed by inserting the 1.1-kb PCR fragment into 
the pCR9.3 vector. A duplex was constructed by two annealing complimentary 
oligonucleotides (5’- AACAC TAACC ATTAC ACTAA ACGGT ACACA GGAAA 
CAGGA GACAC AACTT GCGAC TGTAG AGGAG ACTGC TTTTG TCCAA 
GTGCA T -3’ and 5’- ATGCA CTTGG ACAAA AGCAG TCTCC TCTAC AGTCG 
CAAGT TGTGT CTCCT GTTTC CTGTG TACCG TTTAG TGTAA TGGTT AGTGT 
T -3’).  This 86-bp duplex was cloned into ScaI-digested pCR9.3(AS), forming the 
pCR9.3(RGD) plasmid containing the Ad5 complete sequence (nucleotide 31950-33125) 
and an additional RGD-4C sequence, CDCRGDCFC, in the HI loop between nucleotides 
32679 and 32680.  The previously constructed 5.6-kb fragment was inserted into EcoRI-
digested pCR9.3(RGD) to form pCR11.7(RGD).  The resulting 11.7-kb BamHI band 
from pCR11.7(RGD) was ligated into the previous 21.7-kb BamHI fragment of pAdEasy-
1, resulting in pAdEasy(RGD).  This 33.4-kb plasmid contains the pAdEasy-1 sequence 
and an additional RGD-4C sequence in the HI loop.  All of the insert orientations within 
vectors were determined by sequencing and restriction analysis.   
The cDNA fragment of IL-6 (KpnI/ EcoRV) from the pCR2.1-IL-6 vector was ligated 
into the pShuttle-CMV vector to form the adenoviral vector pShuttle-CMV-IL-6. DNA 
ligation was performed using 50 ng of vector DNA and at least 200 ng of purified insert 
DNA, in a 10 μl volume containing 10 mM Tris-acetate (pH 7.5), 10 mM magnesium 
acetate, 50 mM potassium acetate, 1 mM Adenosine triphosphate (ATP) and 1-5 unit T4 
DNA ligase (Invitrogen, Burlington, ON, Canada) in a 14°C water bath overnight. 
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Figure 4.1 shows an outline of the steps involved in constructed the recombinant fiber-
modified adenovirus AdVIL-6 expressing the transgene IL-6 using the AdEasy(RGD) 
system. Briefly, pShuttle-CMV-IL-6 was digested with PmeI to linearize the shuttle 
vector.  The linearized shuttle vector was treated with alkaline phosphatase, gel purified 
and ethanol precipitated.  The purified DNA was spun down, dried and re-suspended in 
distilled water. A total of 1 μg of the PmeI-digested shuttle vector was then co-
transformed into 100 ng of BJ5183 E. coli cells, which already contained the backbone 
vector pAdEasy(RGD), via electrotransformation (as outlined in Section 4.2.2.6.2).  The 
transformed cells were plated on selective LB-agar plates containing 100μg/ml 
kanamycin overnight. In the following morning, a number of small colonies were 
selected and cultured in LB broth supplemented with 100 μg/ml kanamycin.  The vector 
DNA was isolated by performing mini-preps from bacteria. The DNA was screened using 
restriction enzyme analysis and analyzed on a 0.7% agarose gel. This allowed for positive 
selection of the recombinant vector pAdEasy(RGD)IL-6, which was further transformed 
into DH5α E.coli host bacterial cells using chemical transformation methods. 
The pAdEasy(RGD) IL-6 plasmid DNA was purified using plasmid mini kits (Qiagen, 
Mississauga, ON, Canada) and digested with PacI, releasing a small fragment consisting 
of the kanamycin resistance gene and the origin of replication (ori). To comfirm that PacI 
digestion was complete, electrophoresis was performed on a 0.7% agarose gel. The 
reaction was then cleaned via phenol:chloroform:isoamyl alcohol (25:24:1) extraction 
followed by an ethanol precipitation.  A total of 5 μg of PacI-digested pAdEasy(RGD)IL-6 
DNA was re-suspended in sterile water for use in 293 cells transfection using 
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Lipofectamine (Invitrogen, Burlington, ON, Canada), described below, to produce 
AdV(RGD)IL-6, which is referred to as AdVIL-6. AdVpLpA, the control AdV containing no 
transgene, was previously created and readily available in Dr. Xiang’s lab (180). 
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Figure 4. 1: Schematic overview of the AdEasy system. 
 
The shuttle vector, containing the IL-6 gene, is linearized with PmeI restriction enzyme. 
The pShuttle-CMV-IL-6 and pAdEasy(RGD) are co-transformed into BJ5183 E. coli 
cells to allow homologous recombination between the two vectors, resulting in formation 
of pAdEasy(RGD)-IL-6.  The resulting pAdEasy(RGD)-IL-6 was then infected into 293 
cells for viral production of the replication-deficient recombinant AdV, AdEasy(RGD)-
IL-6 (referred to as AdVIL-6). 
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4.2.3.2 Liposome Transfection 
A liposome-based method was used for transfection of the PacI-digested recombinant 
pAdEasy(RGD)IL-6 DNA into 293 cells to produce the AdVIL-6. The day before 
transfection, 293 cells were re-plated at a cell density of 2×106 cells per T25cm2 flask.  
For transfections, 5 μg of PacI-digested recombinant pAdEasy(RGD)IL-6 was added to 20 
μl of Lipofectamine in serum-free EMEM media and incubated at room temperature for 
30 min.  The DNA:liposomes complexes were added to the flasks and incubated at 37°C 
in a CO2 incubator.  After 4 hours, the serum-free EMEM media was changed to EMEM 
with 10% FBS. The flasks were continually monitored by microscopy for 7-10 days for 
plaque formation.  To maintain ideal growth conditions, the medium was changed every 
3 days.  When the appearance and extension of cytopathic effects (CPE) were observed in 
the flask, the cells were harvested.  The cell pellet was re-suspended in serum free 
EMEM and underwent five freeze/thaw cycles performed at -80°C and 37°C respectively, 
to prepare the initial crude viral lysate.  
4.2.3.3 AdV Amplication and Purification 
4.2.3.3.1 AdV Amplication 
The initial crude viral lysate was amplified by infecting a large number of flasks of 293 
cells.  After infected cell culture pellets were harvested and had undergone five 
freeze/thaws cycles, the sample was spun down and the supernatant was harvested to 
further infect additional 293 flasks. The ration of infection during the amplification was 
one to five, which meant that the AdV derived from one T175cm2 flask can infect 293 
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cells in five T175cm2 flasks. Amplification continued until the number of the flasks of 
infected T175cm2 flask reached to 24. 
4.2.3.3.2 AdV Purification 
After harvesting the infected flasks from the final amplification step, cells were 
subjected to at least five freeze/thaw cycles.  To remove some of the cell debris and as 
much protein as possible, the sample was spun down at 3,000 rpm for 10 min and 10,000 
rpm at 4°C for 15min. The recombinant AdV was then purified using a Double Cesium 
Chloride Gradient method. The supernatant was gently layered on top of a cesium 
chloride (CsCl) discontinuous gradient using Quick-Seal Centrifuge tubes for 
ultracentrifugation.  The discontinuous layer, which removes the majority of cellular 
contaminants and defective viral particles, consisted of 1.25 gm/ml CsCl layered gently 
over a 1.40 gm/ml CsCl layer.  All of the CsCl solutions were prepared using 1X TD 
buffer consisting of 140 mM NaCl, 5 mM KCl, 25 mM Tris and 0.7 mM Na2HPO4.  
Samples were spun in a Beckman ultracentrifuge at 45,000 rpm for 2 hours using a Type 
80 Ti rotor at 20°C.  The lower opalescent band was collected. To completely separate 
infectious from defective viral particles, the collected sample was placed onto a 1.34 
gm/ml CsCl continuous gradient and spun at 45,000 rpm for 18 hours at 20°C, and the 
viral band was carefully aspirated. Finally, to remove the CsCl, the viral sample was 
placed into a Slide-A-lyzer dialyzing cassette (Pierce, Nepean, ON, Canada) and dialyzed 
against 10 mM Tris-HCl pH 7.4, 1 mM MgCl2 buffer solution for several hours at 4°C, 
with several buffer changes.  Glycerol was added to the sample for a final concentration 
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of 10% (v/v) glycerol.  The viral concentration was determined by a spectrophotometric 
reading at A260 with an optical density (O.D.) unit of 1 equivalent to 1010 PFU/ml (181).  
Purified AdV were stored at -80°C until use. 
4.2.3.4 Bone Marrow (BM)-derived DC 
The preparation of bone marrow -derived DCs (BM-DCs) was previously described 
(182). Briefly, BM cells were collected from the femora and tibiae of naïve C57BL/6 
mice. The BM cells were depleted of red blood cells with 0.84% Tris-ammonium 
chloride and plated in DC culture medium [DMEM with 10% FBS, GM-CSF (20 ng/ml; 
R&D System, Minneapolis, MN) and IL-4 (20 ng/ml; R&D System, Minneapolis, MN)].  
On day 3, the non-adherent granulocytes, T cells and B cells were gently removed, and 
fresh media was added.  Two days later, the loosely adherent proliferating DC aggregates 
were dislodged and re-plated.  On day 6 of culture, non-adherent DC cells were harvested 
for phenotypic analysis, OVA pulsing in vitro or AdV transductions. 
4.2.3.5 DC Transduction with AdV 
Six-day cultured DCs were incubated with AdVIL-6 and the control AdVpLpA at a 
multiplicity of infection (MOI) of 150. After viral adsorption for 1 hour at 37°C in 
DMEM in 6-well culture plates, the DC culture medium was replaced with DMEM 
containing 10% FBS and these cells were incubated for another 24 h at 37°C. DCs 
infected with AdVIL-6 and the control AdVpLpA were termed DCAdVIL-6 and DCAdVpLpA, 
respectively.  The infected cells were harvested for phenotypic analysis by flow 
cytometry or examination of IL-6 and the control housekeeping gene GAPDH expression 
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using RT-PCR (as outlined in Section 4.2.1.1 and Section 4.2.1.2). Moreover, the 
supernatants of DCAdVIL-6 and DCAdVpLpA were collected to assay the secretion of IL-6 
using the IL-6 Enzyme linked immunosorbent assay (ELISA) Kit (BD Bioscience, 
Mississauga, ON, Canada). 
4.2.3.6 Preparation of DCOVA, IL-6 Transgene Engineered DCOVA (DCOVA/AdVIL-6) 
and pLpA Transgene Engineered DCOVA (DCOVA/AdVpLpA) 
Non-adherent, 6 day cultured DCs were harvested (as outlined in Section 4.2.3.4), and 
then pulsed with 0.4 mg/ml OVA overnight at 37°C in serum-free AIM-V medium 
(Invitrogen, Burlington, ON, Canada). The following morning, these cells were harvested, 
washed extensively, and referred to as DCOVA. To produce IL-6 transgene engineered 
DCOVA (DCOVA/AdVIL-6) and pLpA transgene engineered DCOVA (DCOVA/AdVpLpA), we 
incubated these DCs with AdVIL-6 and the control AdVpLpA at a multiplicity of infection 
(MOI) of 150 for 3 hours at 37°C in AIM-V medium in 6-well culture plates. After viral 
adsorption, DCs were pulsed with 0.4 mg/ml OVA and AdV overnight at 37°C in the 
AIM-V medium. These DCs infected with AdVIL-6 and the control AdVpLpA and pulsed 
with OVA were termed DCOVA/AdVIL-6 and DCOVA/AdVpLpA, respectively. 
4.2.3.7 Preparation of OVA-specific AdVIL-6 or AdVpLpA-engineered DC-activated 
CD8+ T Cells 
Spleens were removed from OVA-specific TCR transgenic OT I mice and mechanically 
disrupted to obtain a single-cell suspension. The erythrocytes were lysed using 0.84% 
ammonium chloride. The naive CD8+ T cells were enriched by passage through nylon 
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wool columns (C&A Scientific, Manassas, VA), and then further fractionated by negative 
selection using anti-mouse CD4 (L3T4) paramagnetic beads (Invitrogen, Burlington, ON, 
Canada). To generate OVA-specific AdVIL-6 or AdVpLpA-engineered DC-activated CD8+ 
T cells , these naive CD8+ T cells (2×105 cells/ml) were stimulated for 72 h with 
irradiated (4,000 rads) DCOVA/IL-6 or DCOVA/pLpA (1×105 cells/ml), respectively, in the 
presence of IL-2 (10 U/ml). The OVA-specific AdVIL-6 or AdVpLpA-engineered DC-
activated CD8+ T cells were referred to as TA or TB, respectively. 
4.2.4 Immunology Methods 
4.2.4.1 Enzyme linked immunosorbent assay (ELISA) 
To confirm IL-6 expression in the IL-6 transgene-engineered DCs, an ELISA was 
performed using a Mouse IL-6 ELISA Set (BD Bioscience, Mississauga, ON, Canada) in 
accordance with the manufacturer’s protocol.  Briefly, a 96-well plate was coated with 
IL-6 capture antibody diluted in coating buffer (PH 9.5) for incubation overnight at 4 °C. 
The following morning, 96-well plate was washed three times with PBS with 0.05% 
Tween-20 (Bio-Rad, Mississauga, ON, Canada) and blocked with 3% bovine serum 
albumin (BSA) (w/v) in PBS for 1 hour at room temperature. The plate was washed twice 
with PBS with 0.05% (v/v) Tween-20 and standards, along with the culture supernatant 
of DCAdVIL-6 and DCAdVpLpA, as described in Section 4.2.3.5, diluted at some appropriate 
ratio, were added. The plate was incubated for 2 hour at room temperature. Following 
this, the plate was washed 5 times with PBS with 0.05% (v/v) Tween-20 and incubated 
with a 1:1 mixture of Biotin conjugated anti-mouse IL-6 antibody and horseradish 
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peroxidase (HRP) conjugated-streptavidin for 1 hour followed by additional washes.  
Next, 3,3’,5,5’ tetramethylbenzidine (TMB) substrate (TMB Substrate Kit; BD 
Bioscience, Mississauga, ON, Canada) was added to each well and incubated for 30 min 
followed by the addition of 2N H2SO4 (BDH Inc., Toronto, ON, Canada) to stop the 
reaction.  Developed plates were read on a Bio-Rad microplate reader at a wavelength of 
450 nm. Values of samples are found out by plotting OD values against standard curve. 
4.2.4.2 Phenotypic Characterization of Engineered DC and the Engineered DC-
activated CD8+ T Cells 
For phenotypic analysis, DC, DCAdVIL-6 and DCAdVpLpA were stained for 1 h on ice with 
the biotin-conjugated anti-mouse antibodies (2 mg/ml) specific for major 
histocompatibility complex (MHC) class Ⅱ (Iab), CD40, CD54 or CD80. The cells were 
then washed three times with PBS, prior to incubation for an additional 1 hour on ice 
with FITC-conjugated streptavidin. After another three washes with PBS, the cells were 
analyzed by flow cytometry using an Epics XL flow cytometer (Beckman-Coulter, 
Mississauga, ON, Canada). Isotype-matched mAbs were used as controls. 
The method of analyzing the phenotypic characters of the activated T cells is similar as 
that of DCs. Briefly, the engineered DC-activated CD8+ T cells, including TA and TB, 
were stained with biotin-conjugated anti-mouse antibodies specific for CD8, CD25 and 
CD69 followed with FITC-conjugated streptavidin or PE-conjugated anti-mouse 
antibodies specific for CD62 ligand (CD62L) and Fas ligand (FasL), and then analyzed 
by flow cytometry. Isotype-matched mAbs were used as controls. To examine the 
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intracellular expression of cytokines, the above activated T cells were processed using 
Cytofix/CytoPerm Plus with GolgiPlug kit (BD Bioscience, Mississauga, ON, Canada), 
and stained with PE-conjugated anti-mouse perforin antibody, according to the 
manufacturer’s protocol (183). 250ul of fixative/permeabilization buffer was added to the 
engineered DC-activated CD8+ T cells and incubated for 20 min on ice. After being 
washed three times wtih BD Perm/Wash buffer, the fixed/permeabilized cells were 
stained with PE-conjugated anti-mouse perforin antibody for 1 hour on ice in the dark, 
and washed three times with BD Perm/Wash buffer. These cells were then analyzed by 
flow cytometry. Isotype-matched mAbs were used as controls. 
4.2.4.3 Tetramer Staining Assay 
The DCOVA/AdVIL-6 or DCOVA/AdVpLpA were injected intravenous (i.v.) into naïve C57BL/6 
mice (six mouse/group, 1×106 cells /mouse). PBS was used as a control. Six days after 
immunization, 100μl of blood was taken from the tail vein and the blood samples were 
stained with PE-labeled H-2Kb/OVA 257-264 tetramer (Beckman-Coulter, Mississauga, ON, 
Canada) and FITC-labeled anti CD8 antibody for 30 min at room temperature in the dark. 
Lysis/fixative buffer (Beckman-Coulter, Mississauga, ON, Canada) was used to lyse the 
erythrocytes. The cells were washed three times with PBS and analyzed by flow 
cytometry using an Epics XL flow cytometer (Beckman-Coulter, Mississauga, ON, 
Canada). 
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4.2.4.4 In vivo Cytotoxicity Assay 
The In vivo cytotoxicity assay was performed as described previously (182). To 
generate differentially labeled target cells, Splenocytes derived from naïve C57BL/6 mice 
were incubated with high (3.0μM, CFSEhigh) or low (0.6μM, CFSElow) concentrations of 
carboxyfluorescein diacetate succinimidyl ester (CFSE).  CFSEhigh cells were pulsed with 
the OVA I peptide, SINFEKL, and washed extensively to remove free peptide. However, 
the CFSElow cells were not pulsed to become the internal controls.  CFSEhigh and CFSElow 
were co-injected i.v. at a ratio of 1:1 into the above immunized mice described in Section 
4.2.4.3, six days after the final immunization. Sixteen hours after injection, spleens were 
removed from the immunized mice to analyze residual CFSEhigh and CFSElow target cells 
remaining in recipients’ spleens by flow cytometry. 
4.2.4.5 T Cell Survival 
Naïve C57BL/6 mice were injected i.v. with engineered DC-activated CD8+ T cells (TA 
or TB, 5×106 cells /mouse). Six, twelve and thirty days after adoptive transfer, blood was 
taken from the tail vein, and analyzed with the H-2Kb/OVA 257-264 tetramer assay (as 
outlined in Section 4.2.4.3)  to detect the presence of OVA-specific CD8+ T cells in the 
mouse peripheral blood. 
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4.2.5 Animal Studies 
4.2.5.1 DC Vaccine 
For evaluation of tumor prevention, naïve C57BL/6 mice were vaccinated i.v. with 
1×106 engineered DCOVA/AdVIL-6, DCOVA/AdVpLpA or the control PBS, respectively. On day 
8, the mice (8 mice per group) were challenged by i.v. injection with two different doses 
of OVA transgene-expressing BL6-10OVA tumor cells, 0.5×106 and 1×106, respectively. 
Four weeks after tumor cell challenge, these mice were sacrificed and the number of lung 
metastatic tumor colonies was counted. The lung tissues of these mice were further 
analyzed by histological examination. 
4.2.5.2 Adoptive OVA-specific AdVIL-6 or AdVpLpA-engineered DC-activated CD8+ T 
Cell Immunotherapy Model 
Naïve C57BL/6 mice (8 per group) were subcutaneously (s.c.) inoculated with 1×106 
OVA transgene-expressing EG7 tumor cells in their right thighs. After 10 to 11 days, 
when the tumors reached around 8mm in diameter, each mouse received an i.v. injection 
of 2×106 AdVIL-6 or AdVpLpA-engineered DC-activated CD8+ T cells or the control PBS. 
By measuring two perpendicular tumor diameters using a caliper, tumor growth or 
regression were monitored daily. For humanitarian reasons, all mice showing severe 
distress or with tumors that achieved a size of 1.7 cm in diameter were killed. Animals 
were monitored for a total of 70 days. To analyze the anti-tumor immune memory, 8 
weeks after tumor regression, mice showing a decrease in tumor size were re-challenged 
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with a s.c. injection of 1×106 EG7 tumor cells. The tumor growth was monitored as above. 
Naïve C57BL/6 mice were used as controls. 
4.2.6 Histological Examination 
The lung tissues were removed from the immunized mice four weeks after tumor cell 
challenge (as referred in Section 4.2.5.1). The tumor samples were fixed in 10% 
formaldehyde, embedded in paraffin and sliced into sections of 6–7μm thickness. These 
sections were stained with hematoxylin-eosin in accordance with the standard procedures. 
4.2.7 Statistical Analysis 
To compare mouse survival and tumor development between groups, Log-rank tests 
were performed. The significance of differences was determined between groups by 
Student’s t-test using Stat View SE Software (Abacus Concepts, Berkeley, CA). The 
difference was considered statistically significant at P values less than 0.05 (P<0.05). 
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Chapter 5 
RESULTS 
5.1 Part A- IL-6 Engineered Dendritic cell (DC) Vaccine 
5.1.1 Construction of AdV 
To construct the early transcribed regions (E)-1/E3-deleted replication-deficient 
adenovirus (AdV) vectors, we used the AdEasy system under the regulation of the 
cytomegalovirus (CMV) early/immediate promoter/enhancer, which is shown in figure 
5.1A. Since DCs express low levels of ‘Coxsackie virus and Adenovirus receptor’ (CAR) 
and high levels of surface integrins (161-163), a arginine-guanine-aspartate (RGD) motif, 
which can bind to the integrins and stimulate AdV internalization (160, 184), was added 
to the HI loop of the AdV fiber. It is reported that this method can improve gene transfer 
to dendritic cells (DCs) (164-166). As shown in figure 5.1B, AdVIL-6 and the control 
AdVpLpA are the RGD-modified AdV with IL-6 and no transgene insert, respectively. 
Moreover, AdVIL-6 infected DCs will now be referred to as DCAdVIL-6, and AdVpLpA 
infected DCs will be referred to as DCAdVpLpA. 
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Figure 5. 1: Constructed Adenoviral vectors. 
 
  (A)The E1/E3-deleted replication-deficient AdV vectors are under the regulation of the 
CMV early/immediate promoter/enhancer. (B) The RGD-modified AdV was fiber-
modified form of AdV containing the RGD peptide in the HI loop of the fiber knob.  
AdVIL-6 and the control AdVpLpA are the RGD-modified AdV with the IL-6 gene and no 
transgene insert, respectively. ITR, inverted terminal repeat. 
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5.1.2 IL-6 Expression in DCAdVIL-6 
To examine IL-6 expression, RNA extracted from infected DCAdVIL-6 and DCAdVpLpA 
was subjected to RT-PCR analysis. As shown in Figure 5.2A, the expression levels of a 
house keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were similar, 
indicating that similar amounts of RNA from DCAdVIL-6 and DCAdVpLpA were loaded. 
Moreover, a significant amount of IL-6 expression was found in the AdVIL-6-infected 
DCAdVIL-6, but not in the control adenovirus-infected DCAdVpLpA, suggesting the difference 
seen in the IL-6 expression levels resulted from AdVIL-6 infection. To further analyze the 
quantity of IL-6 expression, we conducted an IL-6 detection via Mouse IL-6 ELISA Kit 
(BD Bioscience, Mississauga, ON, Canada). As shown in figure 5.2B, the secretion of 
IL-6 was estimated to be around 1.8μg/ml/106/24h, 0.6μg/ml/106/24h and 
0.02μg/ml/106/24h for DCAdVIL-6, DCAdVpLpA and untreated DCs, respectively. This 
indicates that AdV infection significantly increases the IL-6 secretion from nominal level 
to microgram level and AdVIL-6 infected DCs express a higher level of the IL-6 due to the 
transgene IL-6 expression. 
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Figure 5. 2: Expression of cytokine IL-6. 
 
  (A) RNA was obtained from AdVIL-6 infected DCAdVIL-6 and the control AdVpLpA 
infected DCAdVpLpA cells for examination of IL-6 expression. The first-strand cDNA was 
synthesized from RNA using reverse transcriptase, and the PCRs were conducted using 
sets of primers for IL-6 and the control ‘house-keeping’ gene GAPDH, respectively. 
After 30 cycles, 10μl of the reaction was run on a 1.5% agarose gel. (B) The supernatants 
of DCAdVIL-6, DCAdVpLpA and untreated DCs were measured for expression of IL-6, 
respectively, using an IL-6 ELISA Kit. 
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5.1.3 AdV Enhances the Maturation of DCs 
To assess the phenotypic changes on AdVIL-6-infected DCs, DCAdVIL-6, DCAdVpLpA as 
well as untreated DCs were subjected to phenotypic analysis using flow cytometry. As 
shown in figure 5.3, both AdVIL-6-infected DCs (DCAdVIL-6) and control AdVpLpA-infected 
DCs (DCAdVpLpA) showed a mild to moderate up-regulation of MHC class Ⅱ (Iab), CD40, 
CD54 and CD80 expression, compared to untreated DCs. Since up-regulation of cellular 
expression of these immunological molecules is related to DC maturation, our results 
indicate that AdV-infected DCs become a more mature form of DCs. However, the IL-6 
transgene itself does not affect DC maturation 
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Figure 5. 3: Adenovirus enhances the maturation of DCs. 
 
  The phenotypic changes of DCs were compared by flow cytometry. Un-infected DCs, 
AdVpLpA-infected DCs (DCAdVpLpA) and AdVIL-6-infected DCs (DCAdVIL-6) were harvested 
and analyzed for surface expression of MHC class Ⅱ(Iab), CD11c, CD40, CD54 and 
CD80 molecules using the mouse anti- MHC class Ⅱ(Iab), CD11c , CD40, CD54 and 
CD80 antibodies and the FITC-labeled goat anti-mouse antibody (solid lines). Isotype-
matched monoclonal antibodies (dashed lines) were used as controls. The value in each 
panel represents the percentage of positive cells based on the isotype control.  One of two 
representative experiments is shown. 
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5.1.4 The DCOVA/AdVIL-6 Vaccine Stimulates a Higher Percentage of OVA-specific 
CD8+ T Cells than the Control DCOVA/AdVpLpA Vaccine 
Naïve C57BL/6 mice were immunized with DCOVA/AdVIL-6 or DCOVA/AdVpLpA. Six days 
later, the amount of OVA-specific CD8+ T cells in the peripheral blood was measured 
using PE-labeled H-2Kb/OVA257-264 tetramer staining and FITC-CD8 staining. As 
illustrated in figure 5.4, the percentage of double positive (PE-tetramer+ and FITC-CD8+) 
cells in the total CD8+ population is significantly higher in the DCOVA/AdVIL-6 immunized 
mice (0.6%) compared to the DCOVA/AdVpLpA immunized mice (0.14%) (Student t-test, P-
value< 0.05), with both immunized groups showing a significant difference compared to 
the control PBS immunized mice (Student t-test, P<0.05).  This indicates that 
DCOVA/AdVIL-6 immunization stimulates a stronger OVA-specific CD8+ T cell response, 
compared to DCOVA/AdVpLpA immunization. 
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Figure 5. 4: DCOVA/AdVIL-6 vaccine stimulates a higher percentage of OVA-specific 
CD8+ T cells response than DCOVA/AdVpLpA. 
 
  The DCOVA/AdVIL-6 and DCOVA/AdVpLpA were i.v. injected into naïve C57BL/6 mice (6 
mice per group, 1×106 cells per mouse). Mouse tail blood cells were stained with PE-H-
2Kb/OVAI tetramer (PE-tetramer) and FITC-anti-CD8 antibody (FITC-CD8), and 
analyzed by flow cytometry at day six after immunization. The value in each panel 
represents the percentage of PE tetramer- positive CD8+ T cells versus the total peripheral 
CD8+ T-cell population. The value in parentheses represents the standard deviation (SD).  
A significant difference exists for both the DCOVA/AdVIL-6 and DCOVA/AdVpLpA immunized 
groups compared to the control PBS (Student t-test, P<0.05).  More importantly there was 
a significant difference between the DCOVA/AdVIL-6 immunized and DCOVA/AdVpLpA 
immunized groups (p<0.05), indicated by *. One of two representative experiments is 
shown. 
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5.1.5 The DCOVA/AdVIL-6 Vaccine was More Efficient in Stimulating CD8+ T Cell 
Differentiation into Effector CD8+ CTL than the Control DCOVA/AdVpLpA Vaccine. 
To analyze the ability of DCOVA/AdVIL-6 to induce the differentiation of naïve CD8+ T 
cell into effector CTL, an in vivo cytotoxicity assay was performed.  We adoptively i.v. 
transferred OVAI peptide pulsed splenocytes, strongly labeled with CFSE (CFSEhigh), as 
well as weakly labeled with CFSE (CFSElow, non-peptide pulsed), into recipient mice, 
which had been vaccinated with DCOVA/AdVIL-6 and DCOVA/AdVpLpA, respectively.  Flow 
cytometric analysis was performed to examine the ability of activated T cells to induce 
specific killing of labeled splenocytes (target cells).  In Figure 5.5, because cell killing 
was specifically targeted towards OVA labeled cells, levels of CFSElow cells remained 
unaffected and the level of CFSEhigh cells remaining in the spleen was reduced 
accordingly. Residual CFSEhigh cells remained unchanged in the spleen of the control 
mice and there was substantial loss of the CFSEhigh (OVAI peptide pulsed) cells in 
immunized mice. Among them, the mice immunized with DCOVA/AdVpLpA had a decrease 
of 46% CFSEhigh (OVAI peptide pulsed) cells, whereas the mice immunized with 
DCOVA/AdVIL-6 had a greater degree of loss (93.3%).  This result indicates that 
DCOVA/AdVIL-6 cells were more efficient in stimulating CD8+ T cell differentiation into 
effector CD8+ CTL than DCOVA/AdVpLpA. 
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Figure 5. 5: DCOVA/AdVIL-6 vaccine stimulates CD8+T cell differentiation more 
efficiently into effector CD8+ CTL than DCAdVpLpA. 
  In the in vivo cytotoxicity assay, C57BL/6 mice were immunized i.v. with DCOVA/AdVIL-
6, DCOVA/AdVpLpA or PBS. Six days after immunization, the mice were co-injected i.v. at a 
1:1 ratio of splenocytes labeled with high (3.0 µM, CFSEhigh) and low (0.6 µM, CFSElow) 
concentrations of CFSE and pulsed with OVA I and non-peptide, respectively. Sixteen 
hours after target cell delivery, the residual CFSEhigh and CFSElow target cells remaining 
in the spleens of the recipients were sorted and analyzed by flow cytometry. The value in 
each panel represents the percentage of CFSEhigh cells versus CFSElow cells remaining in 
the spleens. The value in parentheses represents the SD. *, P < 0.05, versus cohorts of 
DCOVA/AdVpLpA cells (Student’s t-test). One representative experiment of three is shown. 
L, Low; H, high. 
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5.1.6 The DCOVA/AdVIL-6 Vaccine Induces More Efficient Protection against Tumor 
Challenge than the Control DCOVA/AdVpLpA Vaccine 
To study whether DCOVA/AdVIL-6 are also capable of inducing enhanced antitumor 
immunity in vivo, we vaccinated mice with DCOVA/AdVIL-6, DCOVA/AdVpLpA and control 
PBS. Eight days later, both low (0.5 × 106 cells, Experiment I) and high (1 × 106 cells, 
Experiment II) doses of BL6-10OVA tumor cells were used to challenge the immunized 
C57BL/6 mice. Four weeks after tumor cell challenge, these mice were sacrificed and the 
number of lung metastatic tumor colonies was counted. The lung tissues from these 
sacrificed mice were removed, fixed in 10% formaldehyde and embedded in paraffin for 
histological analysis. Sections of 6–7μm thickness were stained with hematoxylin-eosin 
according to standard procedures. As shown in table 5.1, after challenge with a low dose 
of BL6-10OVA tumour cells, vaccination with either DCOVA/AdVIL-6 or DCOVA/AdVpLpA was 
sufficient to protect 100% of the mice from tumour growth (8/8 protected). However, 
when mice were challenged with a high dose of tumour cells, DCOVA/AdVpLpA 
immunization was only able to protect 50% of the mice (4/8 protected) while 
DCOVA/AdVIL-6 immunization was still able to protect 100% of the mice from tumor 
growth (8/8 protected). Therefore, vaccination with any of the OVA-pulsed AdV-infected 
DC populations (DCOVA/AdVIL-6 and DCOVA/AdVpLpA) is sufficient to induce protection 
against a challenge of low dose of tumour cells. A distinct effect of immune protection 
derived from differential DC vaccination was only apparent when a higher dose of tumor 
cells are used. As shown in figure 5.6, lung metastases were in the section of lung tissue 
from the mouse immunized with DCOVA/AdVpLpA, but not in lung tissue from the mouse 
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immunized with DCOVA/AdVIL-6.  These data indicate that vaccination using DCOVA/AdVIL-6 
cells is able to induce a stronger antitumor immunity than similar vaccination using 
DCOVA/AdVpLpA. 
Table 5. 1: The DCOVA/AdVIL-6 vaccine induces more efficient protection against tumor 
challenge than the control DCOVA/AdVpLpA vaccine  
________________________________________________________________________ 
 
T cell transfer        Tumor cell challenge      Tumor bearing mice           Median number of                    
lung 
                                                                                    (%)                            tumor colonies 
______________________________________________________________________________ 
 
Exp. IA 
DCOVA/AdVpLpA              BL6-10OVA                            0/8 (0)                                   0 
DCOVA/AdVIL-6                BL6-10OVA                            0/8 (0)                                   0 
PBS                              BL6-10OVA                            8/8 (100)                            >100 
 
Exp. II 
DCOVA/AdVpLpA               BL6-10OVA                             4/8 (50)                           49±23 
DCOVA/AdVIL-6                BL6-10OVA                              0/8 (0)                                 0 
PBS                              BL6-10OVA                               8/8 (100)                          >100 
______________________________________________________________________________ 
A. Naïve C57BL/6 mice were immunized i.v. with engineered DCOVA/AdVIL-6, 
DCOVA/AdVpLpA and the control PBS, respectively. In experiment I, each mouse was 
injected i.v. with 0.5x 106 OVA transgene-expressing BL6-10OVA tumor cells eight 
days after immunization. In experiment II, each mouse was injected i.v. with 1x 106 
BL6-10OVA tumor cells eight days after immunization. These mice were sacrificed 4 
weeks after tumor cell challenge and the number of lung metastatic tumor colonies 
was counted. One representative experiment of three is shown. 
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Figure 5. 6: Histological photomicrographs of lung tissue. 
 
  Naïve C57BL/6 mice were immunized i.v. with engineered DCOVA/AdVIL-6 and 
DCOVA/AdVpLpA, respectively. Eight days after immunization, each mouse was injected i.v. 
with 1x 106 BL6-10OVA tumor cells. These mice were sacrificed 4 weeks after tumor cell 
challenge. (A) Section of the lung tissue from the mouse immunized with DCOVA/AdVIL-6 
shows no lung metastasis. (B) and (C) Sections of the lung tissue from the mouse 
immunized with DCOVA/AdVpLpA  show lung metastatic tumor (arrows). All figures A to C 
stained by hematoxylin and eosin. Magnifications were x10 for A and B, and x20 for C. 
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5.2 Part B- Immune Mechanism underlying the Result of IL-6 Engineered-DC 
Vaccine 
5.2.1 DCOVA/AdVIL-6-activated CD8+ T Cells Display Higher Level of CD62L, FasL 
and Perforin than DCOVA/AdVpLpA-activated CD8+ T Cells 
To produce the active DCOVA/AdVIL-6-activated and DCOVA/AdVpLpA-activated CD8+ T 
cells, naïve CD8+ T cells isolated from OT I mice were incubated with irradiated 
DCOVA/AdVIL-6 and DCOVA/AdVpLpA for 72 h, respectively. As shown in Figure 5.7, both of 
these CD8+ T cells displayed the CD8+ T cell marker (CD8) as well as CD25 and CD69, 
indicating that they are highly activated. However, DCOVA/AdVIL-6-activated CD8+ T cells 
display higher level of CD62L than DCOVA/AdVpLpA-activated CD8+ T cells, indicating that 
DCOVA/AdVIL-6-activated CD8+ T cells have a stronger migration activity and a tendency to 
become memory T cells. Moreover, compared to DCOVA/AdVpLpA-activated CD8+ T cells, 
FasL and perforin, the markers of cytotoxicity, were also highly up-regulated in 
DCOVA/AdVIL-6-activated CD8+ T cells. This result indicates that DCOVA/AdVIL-6-activated 
CD8+ T cells have an increased cytotoxic ability. 
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Figure 5. 7: Phenotypic analysis of DCOVA/AdVIL-6-activated CD8+ T cells (TA) and 
DCOVA/AdVpLpA-activated CD8+ T cells (TB). 
 
Naïve CD8+ T cells were separated from spleen cells of OT I mice, and then activated in 
vitro by incubation with irradiated DCOVA/AdVIL-6 and DCOVA/AdVpLpA for 72 h, respectively. 
The activated CD8+ TA cells and CD8+ TB cells were stained using a panel of FITC-
labelled mAbs (solid lines) for analysis of CD8, CD25, CD69, CD62L, FasL and Perforin, 
or isotype-matched mAbs (dotted lines). The value in each panel represents the 
percentage of positive cells based on the isotype control. Data are representative of two 
experiments with three mice per group. 
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5.2.2 DCOVA/AdVIL-6-activated CD8+ CTL have Prolonged CD8+ T Cell Survival 
A successful DC-based vaccine is critically dependent upon the duration of in vivo 
persistence of the activated CD8+ T cells. To analyze the survival of DCOVA/AdVIL-6-
activated CD8+ CTL cells in vivo, we performed a kinetic study. In the kinetic study, we 
measured the percentage of OVA-specific CD8+ T cells in the peripheral blood of naïve 
C57BL/6 mice with i.v. transfer of DCOVA/AdVIL-6-activated CD8+ T cells (TA) and 
DCOVA/AdVpLpA-activated CD8+ T cells (TB) using PE-labeled H-2Kb/OVA257–264 tetramer 
staining and FITC-CD8 staining at different time points after adoptive transfer. As 
illustrated in Figure 5.8, the number of total OVA-specific CD8+ T cells detected in the 
peripheral blood of the mice with DCOVA/AdVIL-6-activated CD8+ T cells (TA) and 
DCOVA/AdVpLpA-activated CD8+ T cells (TB) transfer accounted for 2.54% and 2.37% of 
the total CD8+ T-cell population, respectively, at day 6 after adoptive transfer. The 
numbers then gradually dropped to 1.45% and 1.00% at day 12, and 1.23% and 0.38% at 
day 30 after adoptive transfer. The number of DCOVA/AdVpLpA-activated CD8+ T cells (TB) 
dropped much faster than that of DCOVA/AdVIL-6-activated CD8+ T cells (TA), indicating 
that the DCOVA/AdVIL-6-activated CD8+ T cells (TA) have prolonged survival in vivo, 
compared with the control DCOVA/AdVpLpA-activated CD8+ T cells (TB). 
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Figure 5. 8: DCOVA/AdVIL-6-activated CD8+ T cells (TA) have prolonged CD8+ T cell 
survival. 
 
  The DCOVA/AdVIL-6-activated CD8+ T cells (TA) and the DCOVA/AdVpLpA-activated CD8+ T 
cells (TB) were injected i.v. into naïve C57BL/6 mice (6 mice per group). Mouse tail 
blood cells were stained with PE-H-2Kb/OVAI tetramer (PE-tetramer), FITC-anti-CD8 
antibody (FITC-CD8) and analyzed by flow cytometry at the indicated time points after 
adoptive transfer. The value in each panel represents the percentage of PE tetramer- 
positive CD8+ T cells versus the total peripheral CD8+ T-cell population. The value in 
parentheses represents the standard deviation (SD). *P<0.05 versus cohorts of AdVpLpA-
engineered DC-activated CD8+ T cells (TB) (Student’s t-test). One representative 
experiment of three is shown. 
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5.2.3 DCOVA/AdVIL-6-activated CD8+ CTL have Stronger Antitumor Immunity than 
DCOVA/AdVpLpA-activated CD8+ CTL and IL-6 Transfection can Enhance CD8+ 
Memory T Cell Development. 
In clinical practice, most candidates for cancer therapy are patients with existing tumor 
burdens. In modeling the clinical case precisely, we must direct our questions of 
therapeutic efficacy to the eradication of established tumor. To target this, we tested the 
effects of DCOVA/AdVIL-6-activated CD8+ T cells (TA) and DCOVA/AdVpLpA-activated CD8+ 
T cells (TB) using a 10-day established EG7 tumor model system. Naïve C57BL6 Mice 
received s.c. injections of 1×106 EG7 tumor cells in their right thighs. At 10-12 days post-
inoculation, these tumors were around 8 mm in diameter and had well-developed 
vasculature. We then injected i.v. 2×106 DCOVA/AdVIL-6-activated CD8+ T cells (TA) or 
DCOVA/AdVpLpA-activated CD8+ T cells (TB), respectively. Control mice were given i.v. 
injections of PBS. Tumor growth within the mice and their mortality rates were then 
monitored daily for up to 70 days. For humanitarian reasons, all mice with tumors that 
achieved a size of 1.7 cm in diameter were sacrificed. Figure 5.9 shows that in the control 
group, the tumors grew very aggressively and all of the mice in this group died within 10 
days of the treatment onset; in the DCOVA/AdVpLpA-activated CD8+ T cells (TB) treated 
group, the tumors grew more slowly than control group but all of the mice in this group 
died within 20 days of the treatment onset. By contrast, all of the mice with tumors that 
had been treated with the DCOVA/AdVIL-6-activated CD8+ T cells (TA) were cured. These 
results suggest that DCOVA/AdVIL-6-activated CD8+ CTL have stronger antitumor immunity 
than DCOVA/AdVpLpA-activated CD8+ CTL. 
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To observe the antitumor immune memory, mice cured of their tumors via DCOVA/AdVIL-
6-activated CD8+ T cells (TA) were again challenged with 1×106 EG7 tumor cells 8 weeks 
subsequent to the tumor regression. The mice in control group were naïve C57BL6 mice. 
The tumor growth was then monitored as above. As shown in figure 5.10, 5 of 8 mice 
that had treated with DCOVA/AdVIL-6-activated CD8+ T cells (TA) did not grow tumors and 
others (3 of 8) grew small tumors, which disappeared within 20 days of the tumor 
inoculation. However, tumors within the control mice grew very aggressively and all of 
the mice in this group died within 20 days of the tumor inoculation. This indicates that 
DCOVA/AdVIL-6-activated CD8+ CTL develop into CD8+ memory T cells more efficiently 
than DCOVA/AdVpLpA-activated CD8+ CTL. Thus, IL-6 secretion would be beneficial to the 
development of CD8+ memory T cells. 
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Figure 5. 9: DCOVA/AdVIL-6-activated CD8+ T cells (TA) have stronger antitumor 
immunity than DCOVA/AdVpLpA-activated CD8+ T cells (TB). 
 
  OVA-expressing EG7 tumor cells (1×106 cells per mouse) were injected s.c. into the 
right thighs of C57BL6 mice (8 per group). At ten to eleven days post-inoculation, when 
the tumors were around 8 mm in diameter, each mouse received an i.v. injection of 2×106 
DCOVA/AdVIL-6-activated CD8+ T cells (TA), DCOVA/AdVpLpA-activated CD8+ T cells (TB), or 
PBS, respectively. Tumor growth or regression was monitored by measuring tumor 
diameter using a caliper daily for up to 70 days. For humanitarian reasons, all mice that 
had tumors with 1.7cm in diameter were sacrificed. 
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Figure 5. 10: DCOVA/AdVIL-6-activated CD8+ T cells (TA) enhance CD8+ memory T cell 
development. 
 
  The mice in the DCOVA/AdVIL-6-activated CD8+ T cells (TA) group were cured of their 
tumors. These mice were again challenged with 1x106 EG7 tumor cells 8 weeks 
subsequent to the tumor regression. At the same time, naïve C57BL6 mice, as a control 
group (8 mice per group), were challenged with EG7 tumor cells. The tumor growth was 
then monitored as above. 
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Chapter 6 
DISCUSSION 
6.1 AdV Enhance the Maturation of DCs 
DCs, as professional antigen presenting cells, can uptake antigen efficiently and have 
high stimulatory activity for T cells (185). In the periphery, the immature DCs capture the 
antigen. This stimulates maturation process, which allows DCs to migrate to regional 
lymph nodes to present antigens to T cells and B cells. DCs have two different stages of 
maturation, immature and mature. Immature DCs are able to capture the antigen 
efficiently whereas they are poor at presenting the antigen to T cells and B cells. On the 
contrary, the mature DCs can not efficiently capture the antigen, but have a potent ability 
to stimulate T cells. Previous reports have shown that immature DCs have low surface 
expression of MHC class Ⅱ (Iab) protein, integrin (CD54) and some costimulatory 
molecules (CD40 and CD80) (186, 187). However, mature DCs are characterized by high 
level of expression of these surface markers (185). DCs are required to be in the mature 
stage to stimulate the immune response and these markers play an important role in the 
process of stimulating T cells. It has been demonstrated that generation of anti-tumor 
immunity by DC vaccines is related to the degree of DC maturation (188).  
The human type 5 replication-deficient recombinant AdV vectors are commonly used 
for transgene delivery. Some previous reports have shown that AdV can mature and 
activate DCs, and can increase the expression of some maturation markers on the surface 
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of  DCs, such as MHC class Ⅱ(Iab) protein, integrin (CD54) and some costimulatory 
molecules (CD40 and CD80) (162, 189-191). Moreover, a recent study showed that the 
Adenovirus-induced maturation of DCs was linked to activation of a 
phosphatidylinositol-3-kinase (PI3K)-mediated TNF-α induction pathway (192). Both 
lipopolysaccharide (LPS) and AdV can activate and mature DCs through an increase in 
tumor necrosis factor-α (TNF-α) expression. LPS activates DC through Toll-like receptor 
4 (TLR-4). TLR-4 signals through MyD88-dependent and MyD88-independent pathway 
(193, 194), can activate transcription factor, nuclear factor (NF)-κB (195), and then 
induce the expression of TNF-α. However, unlike the mechanism of LPS-mediated 
activation and maturation of DCs, the induction of TNF-α expression via the AdV is 
related to the integrin-mediated PI3K pathway to active NF-κB. During AdV infection, 
the knob domain located at the end of Ad fiber binds to the CAR on the target cell. After 
the attachment step, interaction between the RGD modif located on the penton base and 
the αvβ3 or αvβ5 integrins leads to the internalization of the virus through endocytosis. 
However, since DCs do not express CAR but high levels of αvβ3 or αvβ5 integrins, the 
DC infection by AdV was via the binding of the penton base RGD motif of AdV to αvβ3 
or αvβ5 integrins of DCs. It was suggested that both DC activation and the TNF-α 
expression by AdV were also related to the same mechanism (192).  
In this study, our data show that the AdV infected DCAdVIL-6 and DCAdVpLpA up-
regulated the expression of immunologically important molecules (MHC class Ⅱ (Iab), 
CD40, CD54 and CD80), compared with the un-infected DCs, indicating the AdV 
infected DCs are more mature. Moreover, there are no differences between DCAdVIL-6 and 
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DCAdVpLpA in the expression levels of these immunologically important molecules, 
indicating the transgene IL-6 expression itself did not affect DC maturation. This is in 
agreement with the previous literature showing that maturation of DC is dependent only 
on virus entry but not virus gene or transgene expression (196).  
6.2 Engineered DC Vaccine and IL-6 Transgene Engineered DC Vaccine 
DCs play a key role in stimulating T cells that are critical for anti-tumor immunity. 
Based on the role of DCs in immune system, DC-based vaccines have been anticipated as 
a potential treatment for cancer. DCs are engineered to become potential vaccines against 
tumors via pulsing with TAA or peptides and delivery of genes encoding tumor- 
associated antigens into DCs. These antigens can be presented on the surface of DCs with 
the MHC class I molecule, leading to death of the tumor cells through the induction of 
CTL-medicated immune responses. As a further strategy to enhance the ability of DC 
vaccines to induce anti-tumor responses, some genes encoding immunomodulatory 
proteins such as cytokines and chemokines have been transferred into DCs. As such, the 
granulocyte macrophage-colony stimulating factor (GM-CSF) –engineered DC can 
augment the antigen-presenting capacity and the induction of anti-tumor immunity (60, 
197). It was reported that DCs expressing IL-12 transgene can promote induction of 
tumor specific CD4+ T helper (Th) cells and CD8+ CTLs, which enhanced antitumor 
immunity (65, 198). Recently, some reports suggested that the secondary lymphoid tissue 
chemokine (SLC) can induce antitumor responses and the i.t. injection of SLC-expressing 
DCs can inhibit tumor cells in animal models (93, 94, 199). In our lab, we have studied 
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DC vaccines that were genetically modified to express Fms-like tyrosine kinase 3-ligand 
(Flt3L), TNF-α or co-stimulatory molecule 40 ligand (CD40L) in the animal models. It 
has been reported that all of these engineered DC vaccines can stimulate the enhanced 
specific CTL responses and augment antitumor immunity in vivo (67-69).   
The cytokine IL-6 exits widely in organ systems, including the immune system, central 
nervous system, cardiovascular system, hepatic system among others (136). In the 
immune system, IL-6, secreted by T cells and macrophages, acts as a pro-inflammatory 
cytokine that can up-regulate adhesion molecules and induce or augment the production 
of other pro-inflammatory cytokines (200, 201). In addition, IL-6 promotes B cell 
differentiation and proliferation (202, 203). More recently, it has been reported that IL-6 
is a key signal in the development of Th17 cells, but inhibits the formation of the 
regulatory T (Treg) cells (115). Transforming growth factor (TGF)-β signals can induce 
naïve CD4+ T cells toward the suppressor Treg cells. The existence of Treg cells in the 
tumor microenvironment can help tumor cells to escape the lytic activity of activated 
CD8+ CTL, which limits the therapeutic effect of DC-based vaccines. However, addition 
of IL-6 to TGF-β can stimulate Th cells to become Th17 cells, not Treg cells (116). 
Therefore, IL-6 can overcome the Treg-mediated suppression of antigen-specific T cell 
responses in the tumor microenvironment. This function of IL-6 is similar to TNF-α. 
Valencia X et al have demonstrated that TNF-α can also inhibit the suppressive function 
of Treg cells by down-regulating FoxP3 expression (79). At the same time, TNF-α 
infected DCs can also show enhanced antitumor immunity (68). Moreover, it was 
suggested that IL-6 has anti-apoptotic activity on a wild variety of cells, including the 
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naïve and activated T cells (204-206). IL-6 inhibits apoptosis of activation-induced cell 
death of T cells through reduction of the level of T cell receptor (TCR)/CD3-induced 
apoptosis and expression of Fas/ Fas ligand (FasL), but does not reduce the activation of 
T cells(153). However, the impact of genetically modifying DCs with the IL-6 gene has 
not been studied. All of this prompted us to investigate whether enhanced expression of 
IL-6 is able to increase the antitumor immunity response in a DC-based vaccine.  
To asses the effect of IL-6 transgene expression on a DC-based cancer vaccine, we have 
constructed a recombinant adenovirus, AdVIL-6, expressing the mouse IL-6 gene. We then 
infected DCs with AdVIL-6 and examined (i) the effect of AdVIL-6 transfection on DC 
phenotype and function, and (ii) the antitumor effect of DCOVA/AdVIL-6 vaccine in a BL6-
10OVA animal tumor model. As shown in our results, both the IL-6 transgene-engineered 
DC (DCAdVIL-6) and the control DCAdVpLpA displayed higher expression of MHC class Ⅱ
(Iab), CD40, CD54 and CD80 than untreated DCs, indicating AdV can enhance the 
maturation of DCs. Moreover, DCOVA/AdVIL-6 vaccination stimulated stronger OVA-
specific CD8+ T cell and CTL responses compared to the control DCOVA/AdVpLpA 
vaccination.  The tetramer analysis showed increased expression of OVA-specific CD8+ 
T cells for DCOVA/AdVIL-6 immunized mice.  Also, activated T cells from DCOVA/AdVIL-6 
vaccinated mice showed significant OVA-specific killing of 93.3%, compared with only 
46% killing activity derived from activated T cells from the control DCOVA/AdVpLpA 
vaccination mice. Animal studies showed that when challenged with a low dose (0.5×106) 
of BL6-10OVA tumor cells, both vaccination with DCOVA/AdVIL-6 and DCOVA/AdVpLpA 
induced complete protective immunity. Previous work has shown that peptide-pulsed 
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AdV-infected DC populations were sufficient to induce protection against a low dose 
challenge of tumor cells (67). Based on these results, we challenged with a higher dose 
(1×106) of BL6-10OVA tumor cells to analyze the significant differences between 
DCOVA/AdVIL-6 and DCOVA/AdVpLpA immunized mice. The mice vaccinated with 
DCOVA/AdVpLpA protected 50% (4/8) mice from challenge of high dose (1×106) of BL6-
10OVA tumor cells. On the contrary, vaccination with DCOVA/AdVIL-6 still showed complete 
immune protection against the high dose challenge (8/8). This indicates that vaccination 
of mice with DCOVA/AdVIL-6 is able to induce substantially more effective anti-tumor 
immunity in vivo than DCOVA/AdVpLpA. The enhanced anti-tumor immunity of the 
DCOVA/AdVIL-6 may be derived from transgene IL-6 expression. 
To elucidate the immune mechanism underlying the result of DCOVA/AdVIL-6 vaccine, we 
generated the DCOVA/AdVIL-6-activated CD8+ T (TA) and DCOVA/AdVpLpA-activated CD8+ T 
(TB) and assessed their phenotypic characterization, survival and therapeutic effect in 
mice bearing solid EG7 tumors. It has been demonstrated that CTL are able to lyse target 
cells using two molecular mechanisms, one perforin/granzyme-based, the other Fas/FasL 
based (207, 208). The perforin/granzyme pathway is Ca2+-dependent and antigen specific. 
In this pathway, the “pore-forming” protein perforin required to be polymerized and the 
polymerized perforin can act as a tube to guide the granzyme and the outside water into 
the target cell to lyse these cells. Moreover, this pathway occurs only when the target 
cells display specific antigen bound to MHC class I (209, 210). Unlike the 
Perforin/granzyme pathway, the Fas/FasL pathway does not require the presence of Ca2+, 
and it induces antigen-independent and MHC-unrestricted target cell lysis (211, 212). In 
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addition, the time that it takes to lyse the target cell via perforin/granzyme pathway is 
shorter than via Fas/FasL. In our study, results showed that DCOVA/AdVIL-6-activated CD8+ 
T (TA) expressed higher levels of FasL and perforin and displayed stronger tumor cell 
killing activity in mice bearing solid EG7 tumors, compared with the control TB cells, 
indicating these cytotoxicity of TA cells is mediated by both Fas/FasL pathway and 
perforin secretion. Moreover, this result show that the DCOVA/AdVIL-6 stimulate CD8+ T 
cells into effector CTL that had the higher cytotoxic ability, and can explain why the 
activated T cells from DCOVA/AdVIL-6 vaccinated mice showed more significant OVA-
specific antitumor immunity than the activated T cells from the control DCOVA/AdVpLpA 
vaccinated mice. 
The result of the phenotypic characterization of DCOVA/AdVIL-6-activated CD8+ T (TA) 
and DCOVA/AdVpLpA-activated CD8+ T (TB), we found that the expression level of CD62L 
was higher in the DCOVA/AdVIL-6-activated CD8+ T cells (TA), indicating DCOVA/AdVIL-6-
activated CD8+ T cells have a tendency to become memory T (Tm) cells. Moreover, after 
re-challenging mice, which had been cured of their tumors via DCOVA/AdVIL-6-activated 
CD8+ T cells (TA), with EG7 tumor cells 8 weeks subsequent to the tumor regression, the 
results showed that there was no tumor growth or temporary growth which disappeared 
within 20 days of the tumor inoculation. This suggests that DCOVA/AdVIL-6-activated CD8+ 
T cells become T memory cells.  Based on the high level of CD62L on the DCOVA/AdVIL-6-
activated CD8+ T cells and the results of this animal study, it was demonstrated that the 
IL-6-transgene engineered DC vaccine may increase CD8+ memory T cell development.  
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The in vivo persistence of DC-activated CD8+ T cells is an important factor for a DC-
based vaccine. Unfortunately, the vast majority of activated CD8+ T cells die quickly due 
to AICD via apoptosis, which greatly limits treatment efficacy. In our study, we found 
that the number of detected OVA-specific CD8+ T cells in peripheral blood of mice 
treated with DCOVA/AdVIL-6-activated CD8+ T cells and the control DCOVA/AdVpLpA-
activated CD8+ T cells accounted for 2.54% and 2.37% of the total CD8+ T-cell 
population at day 6 after adoptive transfer. However, the numbers gradually dropped to 
1.45% and 1.00% at day 12, and 1.23 and 0.38% at day 30 after adoptive transfer, 
indicating that DCOVA/AdVIL-6-activated CD8+ T cells have prolonged survival in vivo, 
compared with the control DCOVA/AdVpLpA-activated CD8+ T cells.  It has been reported 
that the IL-6 leads to prolonged T-cell survival by preventing AICD, which is IL-2-
independent and does not interfere the process of T-cell activation. (153). IL-6 mediated 
anti-apoptotic activity may account for the increased survival of the DCOVA/AdVIL-6-
activated CD8+ T cells.  
During clinical trails, patients usually bear existing tumor burdens. To correctly 
stimulate a clinical case, we built a mouse model bearing a 10-day established EG7 tumor 
for our animal study. These tumors were around 8 mm in diameter and had well-
developed vasculature. Moreover, many human solid tumors can release 
immunosuppressive levels of IL-10 (99, 107). IL-10 has been identified as a key 
immunomodulatory cytokine that plays a central role in maintaining the proper balance 
between protective immunity against infections/tumors and limiting pro-inflammatory 
responses to self-antigens. It inhibits CD4+ T cell proliferation and reduces 
   92
immunogenicity of DCs, leading to the inhibition of T-cell growth (105), T-cell anergy or 
the induction of Treg cells that suppress antigen-specific T cell responses (101, 106). 
Treg cells, as major immunosuppressive cells, play an important role in escape of tumor 
cells from immune control (107).  It has been reported that addition of IL-6 to TGF-β can 
decrease the formation of Treg cells (116), suggesting IL-6 has the potential to counteract 
IL-10-induced immune suppression. The results of this animal study showed that 100% 
of mice treated with DCOVA/AdVIL-6-activated CD8+ T cells were tumor-free, compared to 
the aggressive tumor growth seen in all 8 tumor-bearing mice treated with the control 
DCOVA/AdVpLpA-activated CD8+ T cells, indicating that DCOVA/AdVIL-6-activated CD8+ T 
cells have enhanced antitumor activity. This may be the result of IL-6 counteracting Treg 
cell-mediated immune suppression.   
Taken together, it has been demonstrated that DCOVA/AdVIL-6-activated CD8+ T cells 
have prolonged survival and increased cytotoxic ability. These two characterizations may 
account for the immune mechanism underlying the result of IL-6 engineered-DC vaccine, 
including that AdVIL-6 infected DCs can stimulate the proliferation of CD8+ CTL and 
have strong antitumor immunity. IL-6 has the potential to convert Treg cell-mediated 
immune suppression. Moreover, the DCOVA/AdVIL-6-activated CD8+ T cells tend to become 
a memory T cells, indicating the IL-6 engineered-DC vaccine enhances memory T cell 
development. Based on these results, we suggest that IL-6 is a candidate for engineering 
DCs suitable for cancer vaccine development. 
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Chapter 7 
CONCLUSIONS 
In the immune system, DCs can take up, process and present TAAs to naïve T cells, and 
stimulate these naïve T cells to become CTLs. This is an important component in the 
initiation of the antitumor immune response. Moreover, IL-6 has proven to suppress 
AICD without interfering with the process of T-cell activation (153) and inhibit the Treg 
cell-mediated immune suppression (115, 116). In this thesis, we have utilized OVA-
pulsed AdVIL-6 infected DCs as a vaccine for cancer therapy. Upon DC maturation, we 
saw up-regulation of expression of MHC class Ⅱ(Iab), CD40, CD54 and CD80 in both 
AdVIL-6-infected DCs and the control AdVpLpA-infected DCs, indicating the AdV can 
enhance the maturation of DCs, independent of the transgene. OVA-pulsed AdVIL-6-
infected DCs (DCOVA/AdVIL-6) stimulate a higher percentage of OVA-specific CD8+ T 
cells and a stronger OVA-specific CTL response than the control OVA-pulsed AdVpLpA-
infected DCs (DCOVA/AdVpLpA). Moreover, immunization with DCOVA/AdVIL-6 induces more 
efficient protective immunity than the control DCOVA/AdVpLpA in C57BL/6 mice. 
In the Part B of this study, we further elucidate the immune mechanism underlying the 
result of IL-6 engineered-DC vaccine by using the DCOVA/AdVIL-6-activated CD8+ T cells. 
Conclusively, the DCOVA/AdVIL-6-engineered DC-activated CD8+ T cells have a prolonged 
survival and stronger cytotoxic ability than the control DCOVA/AdVpLpA-activated CD8+ T 
cells. The DCOVA/AdVIL-6-activated CD8+ T cells also have the tendency to become T 
memory cells. In the animal study, the DCOVA/AdVIL-6-activated CD8+ T cells have more 
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antitumor immunity in the EG7 solid tumor model than the control. Based on these 
results, AdV-mediated IL-6 transgene engineered DC vaccine can stimulate efficient 
CD8+ T cell responses and antitumor immunity via prolonged T cell survival and 
enhanced T cell cytotoxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
   95
Chapter 8 
FUTURE DIRECTIONS 
Although DC-based vaccines have showed durable tumor regression and potential cure 
of metastatic solid cancer in animal models, this immunotherapy has a very low tumor 
response rate in the range of 5%-10% of treated patients in clinic trail (170, 171). It has 
been found that the antitumor activity of activated tumor antigen-specific T cells is 
limited by the tumor cells escaping by releasing IL-10 and their short life in the body of 
patients. Immunosuppressive levels of IL-10 have been found in many human tumors (99, 
107), and this IL-10 blocks tumor-specific helper T type 1 (Th1) responses (100), inhibits 
tumor-specific CD8+ CTL cytotoxicity (108) and supports tumor growth (109, 110) by 
the induction of Treg cells ,which can suppress antigen-specific T-cell responses. 
Therefore, T-cell suppression derived from tumor-secreted IL-10 becomes one of the 
major barriers to immunotherapy for tumors. The short lifespan of the activated tumor 
antigen-specific T cells are another key problem in immunotherapy for cancer. Most of 
the DC-activated T cells in the vaccine died quickly via AICD, and only a small portion 
of effector CTLs survive to kill the target tumor cells, which limits the therapeutic effect 
of DC-based vaccines. 
It has been suggested that IL-6 can overcome the IL-10-induced immune suppression by 
converting Treg cell suppression (115) and has anti-apoptosis activity for the active T 
cells (153). Moreover, in this study, we found AdV-mediated IL-6 transgene engineered 
DC vaccine stimulated CD8+ T cell responses and antitumor immunity via prolonged T 
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cell survival and enhanced T cell cytotoxicity. Therefore, DCs engineered to secret IL-6 
could perhaps be incorporated into a DC-based vaccine applicable to a clinical setting.
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